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CHAPTER I 
 
INTRODUCTION 
 
Epilepsy 
Epilepsy is a common neurological disease defined as experiencing two or more 
unprovoked seizures separated by at least 24 hours (1, 2). While seizures differ in cause, 
severity and regions of brain involvement, all result from abnormal excessive or 
synchronous neuronal activity (3). Epilepsy is considered a spectrum disorder with more 
than 25 associated epilepsy syndromes, ranging from the severe, debilitating Dravet and 
Lennox-Gastaut syndromes to mild and treatable conditions, such as GEFS+ (Genetic 
Epilepsy with Febrile Seizure Plus) and absence epilepsies (4-6). 
Epilepsy currently affects approximately 3 million Americans of all ages and 1% 
of the worldwide population (7). Two-thirds of patients diagnosed with epilepsy have no 
known cause for their disease, however recent evidence suggests most result from 
complex genetic interactions (8, 9). Roughly 20 years of research has resulted in major 
advancements in identifying genes that contribute to the monogenic epilepsies. The genes 
identified are components of neuronal signaling, including nicotinic acetylcholine and 
GABA receptors, chloride channels and voltage-gated potassium and sodium channels 
(10). Identification of these genes provides clues about the etiology of common epilepsy 
syndromes with more complex inheritance. 
 
 
2 
 
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
CO2-
NH3+
Pore
Voltage 
Sensor
D1 D2 D3 D4
β2 β1
R1648H
S662X
M145X
R1407X
T875M K1270T
P1748X
R187W
E211K
R102X
Q54
I1473M
SCN1AMissense
SCN1A Truncation
SCN2AMissense
SCN2A Truncation
F328V
D322N
R1312T
L1330F
L1563V
Voltage-Gated Sodium Channels  
Voltage-gated sodium channels are responsible for the initiation and propagation 
of action potentials and are vital regulators of neuronal excitability. Voltage-gated 
sodium channel brain complexes were identified as a single α subunit associated with 
auxiliary β subunits (11). The α structure contains four homologous domains (D1-D4), 
each consisting of six α–helical transmembrane segments (S1-S6) (12). S4 of each 
domain is positively charged and contains the voltage sensors of the complex, which 
initiate channel activation (Figure 1.1) (13-19). Furthermore, there is evidence of S4/D4 
having a unique role in inactivation (12, 16, 20). The β subunits (β1-β4) are single 
transmembrane segments that modulate voltage dependence, kinetics and localization of 
the α subunits (21, 22). The α subunits primarily expressed in the brain are encoded by 
SCN1A, SCN2A, SCN3A and SCN8A (12, 23-25). SCN1A and SCN3A channels are 
located mainly in neuronal cell bodies, SCN2A channels are localized to dendrites, 
unmyelinated or pre-myelinated axons and SCN8A channels are found in dendrites and 
the nodes of Ranvier (26-30).  
 
 
Figure 1.1 Voltage-Gated Sodium Channel Structure 
Missense and truncation mutations of SCN1A and SCN2A described in the introduction are indicated. 
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Voltage-Gated Sodium Channels and Epilepsy  
Currently, nearly 900 mutations in SCN1A have been reported in patients with 
various types of epilepsy, making it the most common cause of monogenic epilepsy (31). 
Mutations in voltage-gated sodium channels are responsible for several types of human 
epilepsy, including GEFS+ and Dravet Syndrome, formerly known as Severe Myoclonic 
Epilepsy of Infancy (10). GEFS+ is a benign, childhood-onset syndrome with autosomal 
dominant inheritance (OMIM 604233). This familial syndrome is characterized by febrile 
seizures that persist beyond six years of age and afebrile, generalized seizure types later 
in life (32, 33). In 1998, the GEFS+ mutation SCN1B
C121W was identified in the β1 
subunit gene (34). The effect of this mutation was impaired modulation of the sodium 
channel α subunit (35). In 1999, linkage analysis of two large families identified a second 
GEFS+ locus localized to chromosome 2 (36, 37). The nonrecombinant interval 
contained a sodium channel gene cluster that includes SCN1A, SCN2A, SCN3A and 
SCN9A. It was found that affected individuals from one family were heterozygous for 
SCN1A
R1648H
 and affected members from another family were heterozygous for 
SCN1A
T875M
 (38). When the SCN1A
T875M
 and SCN1A
R1648H
 mutations were 
heterologously expressed with β1 and β2 subunits, both GEFS+ mutations exhibited 
noninactivating inward sodium currents (39). Additionally, single channel analysis of 
SCN1A
R1648H
 activity revealed mutants had a higher probability of late channel openings 
(39). The data suggest that these GEFS+ variants result in gain-of-function mutations 
caused by defects in sodium channel inactivation, thereby enhancing sodium current. 
Persistent sodium influx is hypothesized to extend neuronal depolarization, initiate 
hyperexcitability and increase seizure susceptibility (39).  
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Dravet syndrome is the phenotype most frequently associated with mutations of 
SCN1A (OMIM 607208) (40). Over 80% of reported SCN1A mutations have been 
identified in Dravet syndrome or its variant, severe myoclonic epilepsy, borderline 
(SMEB) (31, 40). Approximately 90% of SCN1A mutations found in Dravet patients 
arose de novo and nearly half are nonsense, frameshift or splice site mutations resulting 
in protein truncation (10, 41, 42). This syndrome is characterized by infant-onset 
generalized clonic, generalized tonic-clonic or hemiclonic seizures, often precipitated by 
fever. Although development is normal prior to disease onset, progression is often 
coupled to a severe decline of psychomotor and cognitive development (43, 44). Dravet 
patients develop other types of seizures, including absence and partial seizures and 
respond poorly to anti-epileptic drugs.  
 Recently, seven SCN1A variants were identified by exome sequencing of patients 
with infantile spasms or Lennox-Gastaut (45). These epileptic encephalopathies, like 
Dravet syndrome, are severe epilepsy disorders characterized by early seizure onset with 
cognitive and behavioral delays due to regular epileptic activity (45). 
A smaller number of mutations have been reported in the other neuronal sodium 
channel genes SCN2A, SCN3A and SCN8A. SCN2A is a paralogous sodium channel gene 
closely linked to SCN1A on chromosome 2. Several missense mutations in SCN2A have 
been detected in patients with Benign Familial Neonatal-Infantile Seizures (BFNIS), 
GEFS+, Dravet and Ohtahara syndromes (46, 47). Interestingly, recent studies have 
attributed several SCN2A mutations to intellectual disability and autism (48, 49). This is 
of particular significance as estimates predict epilepsy affects 7-46% of autism spectrum 
5 
 
patients (50-52). Furthermore, epilepsy occurs more often in autism patients who also 
have an intellectual disability (53).  
BFNIS is characterized by the onset of afebrile generalized seizures typically 
between 2 days and 3.5 months of life, which spontaneously remit by age one (54). 
Twelve SCN2A missense mutations have been found in BFNIS patients (55-60). These 
BFNIS SCN2A mutants exhibit a wide range of functional abnormalities hypothesized to 
contribute to seizure generation (58-62). Two mutations, SCN2A
R187W
 and SCN2A
R1918H
, 
have been identified in GEFS+ patients (63, 64). Electrophysiological recordings 
illustrate abnormalities that may be responsible for the hyperexcitability leading to 
seizures at the neuronal level (64). Seven missense mutations  and
 
 the nonsense mutation 
SCN2A
R102X
 were all identified in Dravet patients (65-69). Several SCN2A Dravet 
mutations have been expressed in heterologous systems and displayed abnormalities 
suggestive of epileptiform activities (64, 67, 70). 
The SCN2A
A263V
 missense mutation was identified in a set of monozygotic twins 
with Ohtahara syndrome (47). Ohtahara syndrome is classified as an early onset epileptic 
encephalopathy, characterized by developmental impairment and devastating seizures 
starting at birth (71). The Ohtahara diagnosis was based on neonatal seizures and a 
distinct EEG pattern. Additionally, both twins had brain structure abnormalities, 
characteristic of a progressive neurodegenerative disease (47). Furthermore, the 
SCN2A
R853Q
 missense mutation was identified in two unrelated patients, diagnosed with 
either infantile spasms or Lennox-Gastaut, two epileptic encephalopathies (45). 
Five mutations of SCN3A have been identified in childhood epilepsy. The 
missense mutation SCN3A
K345Q
 was found in an individual with partial epilepsy (72). 
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Functional analysis of SCN3A
K345Q
 revealed altered sodium currents providing a 
pathophysiological basis for the epilepsy linked mutation (73). Our laboratory identified 
four additional SCN3A mutations in a cohort of pediatric patients with cryptogenic focal 
epilepsy (74). In vitro analysis of all four mutations demonstrated significant functional 
defects including increased levels of persistent current and increased ramp current (74). 
Alterations in ramp current and persistent current have both previously been indicated in 
epilepsy related mutations (39, 72, 75-78). 
Advances in whole genome sequencing allowed for recent identification of 
SCN8A mutations involved in the severe epileptic encephalopathies. The SCN8A
N1768B
 
missense mutation resulted in early-onset seizures, autism, intellectual disability, ataxia 
and sudden unexplained death in epilepsy (SUDEP) (79). The functional consequences of 
the mutation were evaluated in vitro, revealing a remarkable increase in sodium current, 
incomplete channel inactivation, increased spontaneous firing and firing frequency (79). 
Two additional missense mutations, SCN8A
G214D
 and SCN8A
L875Q
, were identified in 
patients diagnosed with infantile spasms or Lennox-Gastaut. These SCN8A mutations are 
predicted to increase neuronal excitability, which has previously been implicated in 
seizure development. 
Several microdeletions and duplications of the voltage gated sodium channel gene 
cluster (2q24) have been identified. Chromosomal deletions of 2q24 have been described 
in patients who suffer from epilepsy (80-94). A broad disparity in seizure characteristics 
and diagnosis has been detailed in 2q24 deletions, ranging from infantile spasms, minor 
convulsions and sporadic myoclonic jerks to generalized tonic-clonic seizures, status 
epilepticus and Dravet syndrome (83). Five cases of 2q24 duplications have been 
7 
 
implicated in epilepsy. These duplications all resulted in early-onset infantile seizures and 
global developmental delays (95-99). 
 
Variable Expressivity of Sodium Channel Mutations in Epilepsy 
A common feature of inherited epilepsy due to a sodium channel mutation is that 
family members who carry the same mutation often display a difference in the clinical 
severity of the disease. This is seen in both GEFS+ and Dravet syndrome. In a GEFS+ 
family carrying the SCN1A
T875M
 mutation, half of the affected family members had only 
febrile seizures, while the other mutation carriers had more severe types of seizures as 
adults, including generalized tonic-clonic, absence, atonic and hemicorporeal clonic 
seizures (37, 38). In another GEFS+ family with the SCN1A
K1270T
 mutation, eleven 
family members had only febrile seizures plus and five family members had evidence of 
temporal lobe epilepsy (100).  
The SCN2A
A263V
 mutation implicated in monozygotic twins with Ohtahara 
syndrome was previously identified in a patient with an epileptic encephalopathy 
resembling BFNIS (59). While the BFNIS patient had neonatal onset seizures and late 
onset episodic symptoms, the dramatic characteristics identified in the Ohtahara patients 
were not observed (47, 59).  
In rare cases, Dravet patients have inherited an SCN1A mutation from a mildly 
affected parent (101-103). Gennaro and colleagues described a family in which two 
siblings with Dravet syndrome inherited the SCN1A
P1748fsX1779
 mutation from their 
mother, who had only a single febrile seizure in childhood (102). Two SCN1A truncation 
mutations have been identified that did not result in Dravet syndrome (104). Instead, 
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SCN1A
S662X
 and SCN1A
M145fsx148
 produced GEFS+ and focal seizures, much milder forms 
of epilepsy not commonly associated with SCN1A truncations (104).  
Variable expressivity suggests that other factors in addition to a primary mutation 
influence the clinical manifestation of epilepsy. This could include stochastic events 
during development, accumulation of somatic mutations during the lifetime of an 
individual or environmental insults such as trauma (105). Variation in inheritance of 
other genetic risk alleles in different family members may also modify the clinical 
severity of epilepsy. 
 
Epilepsy Models With Sodium Channel Mutations  
Several mouse models with seizure-related phenotypes recapitulating GEFS+ and 
Dravet syndrome have been generated by introducing mutations in voltage-gated sodium 
channel α subunits. A GEFS+ model was developed by knocking-in the SCN1AR1648H 
mutation into the orthologous mouse gene (106). The Scn1a
tm1.1Aesc
 mouse allele is 
referred to as Scn1a
R1648H
. To study Dravet syndrome, we and others have developed 
targeted null alleles of Scn1a (107, 108). The mouse model Scn1a
tm1Kzy
, a knock-in of the 
SCN1A
R1407X
 mutation,
 
was generated to examine the effects of truncated Scn1a (109). 
SCN1A
R1648H
 was the first human GEFS+ mutation studied in vivo. 
Scn1a
R1648H/R1648H
 homozygous mice experienced premature lethality by postnatal day 26 
(P26) (106). Behavioral observations revealed both heterozygous and homozygous 
mutant animals exhibited spontaneous, generalized seizures that were confirmed by 
electrocorticography (ECoG) recordings (106). Heterozygous mutant mice were more 
susceptible to seizure induction by the chemiconvulsant flurothyl and therefore had 
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reduced times to seizure onset (106). Flurothyl-induced seizure thresholds were restored 
to wildtype levels by administration of the anticonvulsant valproic acid, commonly used 
to treat GEFS+ patients, validating the knock-in as a model for GEFS+ (106). 
Electrophysiological analysis revealed cortical GABAergic bipolar interneurons from 
heterozygous Scn1a
R1648H/+
 and homozygous Scn1a
R1648H/R1648H
 mice displayed reduced 
total sodium current amplitudes, increased use-dependence and slower recovery from 
inactivation (106). Additionally, homozygous animals had a significant reduction in 
action potential firing in these interneurons (106). It is hypothesized that reduced 
excitability of GABAergic interneurons is a key contributor to seizure generation in the 
Scn1a
R1648H/+
 GEFS+ model (106). 
A Dravet mouse model, Scn1a
tm1Wac
, was generated by disruption of the Scn1a 
gene. Scn1a
KO/KO
 homozygous null mice exhibited spontaneous seizures and ataxia by 
P9, with premature lethality by P15 (110). Scn1a
KO/+
 heterozygous mice displayed 
frequent, spontaneous seizures that were confirmed by ECoG recordings (110). Scn1a
KO/+
 
heterozygotes experienced sporadic death beginning at P21, with 40% lethality by the 
15
th
 week of life (110). Electrophysiological analysis of isolated neurons revealed a 
significant reduction of sodium current levels in hippocampal GABAergic interneurons 
from Scn1a
KO/+
 heterozygous and Scn1a
KO/KO 
homozygous mice (110). GABAergic 
interneurons also displayed significant decreases in action potential firing, frequency and 
amplitude in both Scn1a
KO/+
 heterozygous and Scn1a
KO/KO
 homozygous mice (110). 
These abnormalities are indicative of reduced GABAergic transmission, a major 
contributor to neuronal hyperexcitability and seizure generation. In addition to the seizure 
phenotype, Scn1a
KO/+
 heterozygous mice display autism-spectrum features, including 
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hyperactivity, stereotyped behaviors, social interaction deficits and impaired context-
dependent spatial memory (111). SUDEP was also shown to occur in Scn1a
KO/+
 
heterozygous mice (112). SUDEP in Scn1a
KO/+
 mice is hypothesized to occur from 
seizure-induced parasympathetic hyperactivity resulting in lethal bradycardia and 
electrical dysfunction in the heart (112).  
An additional knock-in model of Dravet was generated carrying a premature stop 
codon recapitulating the human SCN1A
R1407X
 mutation identified in three unrelated 
patients (101, 109, 113, 114). At P12, homozygous Scn1a
R1407X/R1407X
 mice exhibited 
tonic-clonic seizures confirmed by ECoG and experienced premature lethality by P21 
(109). Heterozygous Scn1a
R1407X/+
 mice developed seizures at P21, with a 40% mortality 
rate by three months of age, similar to the heterozygous Scn1a
KO/+
 null allele (109).  
Our laboratory has developed the mouse model Tg(Eno2-Scn2a1*)Q54Mm with a 
missense mutation of Scn2a, designated Scn2a
Q54
 (Q54), which resembles an epilepsy 
phenotype of human patients. The transgenic Q54 mouse has a gain-of-function mutation 
[GAL(879-881)QQQ], located in the S4-S5 intracellular linker in D2. Q54 mice have a 
progressive epilepsy phenotype which begins with brief, focal motor seizures (115). As 
they age, Q54 mice exhibit more frequent focal seizures, along with secondarily 
generalized seizures and have a reduced lifespan (115). Recordings of isolated excitatory 
hippocampal pyramidal neurons from Q54 mice revealed increased persistent sodium 
current which is hypothesized to contribute to seizure generation by increasing neuronal 
hyperexcitability (115). Functional studies of several human GEFS+ mutations in 
heterologous expression systems have also shown increased persistent current of similar 
magnitude (39, 77, 116). Hippocampal slice recordings from Q54 mice demonstrated 
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network hyperexcitability during recording of spontaneous and evoked activity, 
supporting the hypothesis that increased persistent current leads to neuronal 
hyperexcitability (117). 
 
Genetic Background Influences Epilepsy Models 
A common feature of seizure mouse models, including sodium channel mutants, 
is that seizure frequency and animal survival varies significantly depending on the 
genetic background of the mouse. This supports the idea of genetic modifiers in epilepsy. 
Consequently, these models provide a useful system for identifying modifier genes that 
may also contribute to variable expressivity in human epilepsy patients. Genes that 
influence a mutant phenotype can be identified systematically by crossing the mutation 
onto different background strains. Modifier loci have been mapped for several diseases in 
human and mouse, including cystic fibrosis, long QT syndrome, cancer, retinal, cochlear 
and motor neuron degeneration, aganglionosis, otocephaly, tremor and dystonia (118-
126). Modifier genes have been identified for several of these loci (120, 126-132). 
 Early studies revealed that there were considerable differences in seizure 
susceptibility dependent on genetic strain background (133, 134). Ferraro and colleagues 
demonstrated that genetic factors in C57BL/6J (B6) and DBA/2J (DBA) influence 
seizure susceptibility, with the B6 strain being far more seizure resistant than the DBA 
strain to a variety of seizure induction methods (135-140). Genetic mapping approaches 
identified Kcnj10, an inward rectifying potassium channel, as a candidate gene for seizure 
susceptibility in these two strains (141, 142). 
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Scn1a
KO/+
 heterozygotes on the B6 strain have an 80% lethality rate by 13 weeks 
of age and frequent, spontaneous seizure activity (107). When Scn1a
KO/+ 
was bred to and 
maintained on the 129/SvJ (129) strain, only 10% of heterozygotes died by 15 weeks and 
seizure activity was not observed (107). Loss of Scn1a is more severe on the B6 strain, 
suggesting the 129 strain contributes modifier genes that improve the epilepsy phenotype. 
Also, the Scn1a
R1407X
 mutation was found to be far less penetrate on the 129 strain (109). 
Q54 mice on the B6 strain exhibit a low incidence of seizures, with less than 20% 
having seizures at three months of age and a 75% survival rate to six months of age 
(143). When B6.Q54 mice are crossed to the SJL/J (SJL) strain, the resulting F1 
generation display a high incidence of seizures (>80%) with early onset and only 25% 
survival to six months of age (143). This observation indicates the SJL strain contributes 
dominant modifiers which affect the severity of the epilepsy phenotype (143). Genetic 
mapping was performed which identified two modifier loci responsible for the strain 
difference: Moe1 (Modifier of Epilepsy 1) and Moe2 (143). The voltage-gated potassium 
channel Kcnv2 was identified as the modifier gene for Moe2 (144, 145). Identification 
and verification of modifier genes in Moe1 is discussed in Chapters II and III. 
 
Genetic Modifiers of Epilepsy 
The idea of genetic modifiers influencing clinical severity is becoming 
increasingly important for understanding the pathophysiology of inherited disease. 
Several genes have already been identified in mouse models which alter seizure 
phenotype and verified in human epilepsy patients (145, 146) 
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 Scn8a has been identified as a modifier of Dravet syndrome. The Scn8a
med-jo 
mouse model contains a missense mutation that results in neuromuscular abnormalities, 
but has increased thresholds to seizure induction (147-152). When Scn8a
med-jo
 
heterozygotes were crossed with Scn1a
KO/+
 heterozygotes to generate double 
heterozygous mutants, the Scn8a
med-jo
 allele was able to rescue reduced seizure thresholds 
of Scn1a
KO/+
 mice and improve their premature lethality (148). These findings suggest 
Scn8a can improve the severity of the Scn1a seizure phenotype.  
 The calcium channel mutant Cacna1a
tg/tg
 recapitulates absence epilepsy and was 
identified as a modifier of the temporal lobe epilepsy model Kcna1. Kcna1 mutants lack 
the Kv1.1 α-subunit of the Shaker-type potassium (K+) channels and therefore the loss of 
K+ channel regulation of action potential firing. Kcna1
KO/KO 
null mutants experienced 
premature lethality with a 26% survival rate to ten weeks of age and frequent, severe, 
tonic-clonic seizures (153). When Cacna1a
tg/tg
 is crossed to Kcna1
KO/KO
 nulls to generate 
double homozygous mutants, 87% of animals survived to ten weeks of age (153). 
Additionally, double homozygous mutants lacked absence seizures and had a 60% and 
80% reduction in tonic-clonic frequency and length of seizure, respectively (153). The 
modifier effect is hypothesized to be the reduced neurotransmission of Cacna1a
tg/tg
 
diminishing Kcna1
KO/KO 
hyperexcitability.  
 Recent work has suggested human variants in CACNA1A and SCN9A modify the 
Dravet syndrome phenotype. Patients with mutations in both CACNA1A and SCN1A 
experienced higher rates of absence seizures, earlier seizure onset and significantly more 
prolonged seizures compared to Dravet patients with only a SCN1A mutation (146). The 
SCN9A
N641Y
 mutation was identified in a large family with 21 individuals experiencing 
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febrile seizure before six years of age (154, 155). Ten of the affected family members 
continued with subsequent afebrile seizures (154, 155). Due to the expansive phenotype 
seen in SCN9A
N641Y
 patients, it was hypothesized that SCN9A may act as a genetic 
modifier of epilepsy. Singh et al. identified SCN9A mutations in seven Dravet syndrome 
patients. Six of these patients were also positive for mild SCN1A missense mutations not 
usually associated with Dravet (155). Furthermore, five SCN9A variants were identified 
in 18 Dravet syndrome patients negative for SCN1A mutations (156). The same study 
also identified seven additional SCN9A variants in SCN1A positive Dravet patients (156). 
The results suggest that variants in SCN9A alone or in combination with SCN1A missense 
mutations, result in Dravet syndrome (155, 156).  
 We demonstrated the voltage-gated potassium and sodium channel mutants 
Kcnq2
V182M/+
 and Scn1a
R1648H/+
 were modifiers of the Q54 seizure model (157, 158). 
Kcnq2
V182M/+
 heterozygous animals have a reduced threshold to seizure induction but no 
spontaneous seizure activity (159). When Kcnq2
V182M/+
 heterozygotes were combined 
with Q54, double mutants experienced early-onset, tonic-clonic seizures and juvenile 
lethality by three weeks of age, unlike the single mutant littermates (158). When 
Scn1a
R1648H/+
 heterozygotes were combined with Q54, double heterozygous mutants 
experienced 100% mortality by P24 and frequent, spontaneous tonic-clonic seizures 
(157). These experiments are detailed in Chapter IV. These modifier effects demonstrate 
that neuronal excitability is influenced by the net activity of ion channels (157). 
 Supporting the role for human genetic modifiers of epilepsy, mutations have been 
identified in CACNA1A, KCNJ10, KCNQ2 and KCNV2 in patients with absence, 
generalized, BFNIS and partial epilepsies, respectively (160-165). 
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Conclusions and Specific Aims 
As described throughout the introduction, epilepsy is a common neurological 
disorder with a wide spectrum of phenotypic severity. Among monogenic epilepsies, like 
Dravet syndrome and GEFS+, affected family members who possess the same mutation 
can have dramatic differences in the clinical presentation of their disease. This suggests 
that other factors, including genetic, must modify the primary mutation, resulting in a 
more or less severe phenotype.  
Genetic epilepsies with complex inheritance likely account for a considerable 
amount of epilepsies with unknown origin (166). In complex inheritance, each individual 
gene may have only a small effect on clinical severity of epilepsy, but in combination 
with risk alleles in other genes, the additive effects can be devastating.  
Mutations in voltage-gated sodium channels are major contributors to genetic 
epilepsies, with 80% of Dravet syndrome and 10% of GEFS+ patients having mutations 
in SCN1A (167). Generation of mouse models recapitulating voltage-gated sodium and 
other neuronal ion channel mutations have allowed for more accurate models of Dravet 
syndrome, GEFS+, absence and temporal lobe epilepsies. The in vivo models are not only 
beneficial to assess behavioral consequences of ion channel mutations, but are also used 
to study the molecular mechanisms altered by mutations, therefore expanding our 
understanding of epilepsy. An increasing amount of evidence from these models has 
shown that seizure phenotypes resulting from gene mutations are modified by the genetic 
strain background. 
 The Q54 transgenic mouse model has a gain-of-function mutation that results in 
persistent sodium current and epilepsy. Q54 mice on the B6 strain exhibit a low incidence 
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of seizures and a relatively normal lifespan (143). When crossed to the SJL strain, the 
resulting F1.Q54 offspring display a high seizure frequency with early onset and 
significantly reduced survival (143). Genetic mapping identified two modifier loci 
responsible for the strain difference in Q54 mice: Moe1 and Moe2 (143, 145).  
I proposed to identify and evaluate candidate genes that alter seizure susceptibility 
at the Moe1 locus through the following specific aims: 
 
Specific Aim 1. To fine map Moe1 on chromosome 11 to ≤ 10 Mb using 
interval-specific congenics and perform RNA-Seq to identify candidate genes. 
 
Specific Aim 2. To test Moe1 candidate modifier genes by transgenic transfer of 
the modified phenotype. 
 
In Specific Aim 1, I utilized interval-specific congenic lines to fine-map Moe1 
and narrow the modifier interval. We then used a next-generation sequencing technique, 
RNA-Seq, to evaluate differences in gene and transcript expression, as well as coding 
sequence, between B6 and SJL strains. Fine mapping and RNA-Seq suggested several 
candidate modifier genes, including Cacna1g and Hlf, for Moe1. These results are 
described in detail in Chapter II, modified from Hawkins & Kearney, 2012. I 
hypothesized candidate genes identified by fine mapping and RNA-Seq contributed to the 
variable phenotype of Q54. 
In Specific Aim 2, I tested the modifier potential of Cacna1g and Hlf by 
systematically evaluating the candidate modifier genes through generation of Cacna1g 
BAC transgenic and Hlf targeted knockout animal models. I tested their ability to 
enhance or reduce seizure severity of the Q54 phenotype by generating double mutant 
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animals. Descriptions of these experiments and validation of Cacna1g and Hlf as 
candidate modifier genes of the Q54 phenotype are detailed in Chapter III. 
I also proposed Specific Aim 3, which focused on taking a functional candidate 
gene approach to evaluate known epilepsy mutations on the Scn1a
R1648H/+
 phenotype. 
 
Specific Aim 3. To test the Q54 and Kcnq2
V182M/+
 epilepsy models as functional 
candidate modifiers of the GEFS+ knock-in model Scn1a
R1648H/+
.  
 
To assess the modifier potential of Q54 and Kcnq2
V182M/+ 
mutations on the 
Scn1a
R1648H/+
 phenotype, we generated double mutant mice. I then utilized ECoG to 
monitor seizure activity in our mutants.
 
I hypothesized that by combining reduced 
GABAergic transmission from Scn1a
R1648H/+
 with reduced seizure thresholds from the 
Kcnq2
V182M/+
 mutation or hyperexcitability from Q54, a severe seizure phenotype would 
result in each cross. These results are described in detail in Chapter IV, modified from 
Hawkins et al., 2011. 
Identification of modifier genes that improve or exacerbate epilepsy may increase 
the understanding of the molecular events of epileptogenesis, advance molecular 
diagnostic capabilities and identify novel therapeutic targets for the improved treatment 
of human patients 
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CHAPTER II 
 
CONFIRMATION OF AN EPILEPSY MODIFIER LOCUS ON MOUSE 
CHROMOSOME 11 AND CANDIDATE GENE ANALYSIS BY RNA-SEQ
*
 
 
Introduction 
Mutations in voltage-gated sodium channels are responsible for several types of 
human epilepsy (1). Mutations in SCN1A were first identified in patients with Genetic 
Epilepsy with Febrile Seizure Plus (GEFS+) (2). Subsequently, SCN1A mutations were 
identified in patients with Dravet, a severe infant-onset epileptic encephalopathy (3). To 
date, nearly 900 epilepsy mutations in SCN1A have been reported. A smaller number of 
mutations in SCN2A have been identified in patients with benign familial neonatal-
infantile seizures (BFNIS), GEFS+, Dravet and Ohtahara syndromes. (4). Affected family 
members with the same sodium channel mutation often display variability in the clinical 
severity of their disease, a common feature of genetic epilepsy. This suggests that 
epilepsy phenotype is influenced by other factors, which may include genetic modifiers. 
A common feature of mouse seizure models, including sodium channel mutants, 
is that seizure susceptibility and severity vary significantly depending on the genetic 
strain background. This indicates that complex genetics, for example genetic modifiers, 
contribute to the variable phenotype observed in seizure models. These mouse models 
provide a useful system for identifying modifier genes that may also contribute to 
variable expressivity in human epilepsy patients. Genes that influence a mutant phenotype 
 
 
* Modified from: Hawkins, NA and Kearney JA. (2012) Confirmation of an epilepsy modifier locus on 
mouse chromosome 11 and candidate gene analysis by RNA-Seq. Genes Brain Behav, 4, 452-460. 
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can be identified systematically by evaluating the seizure phenotype on different 
background strains. Several strain-dependent seizure susceptibility loci and genes have 
already been identified (5-16). 
The transgenic mouse model Scn2a
Q54
 (Q54) has an epilepsy phenotype due to a 
mutation in Scn2a that slows channel inactivation and results in persistent sodium current 
(17). Severity of the epilepsy phenotype in Q54 mice is highly dependent on the genetic 
background. The phenotype is less severe on the resistant C57BL/6J (B6) strain, while it 
is more severe on the SJL/J (SJL) strain. We previously mapped two loci, Moe1 
(Modifier of epilepsy) on chromosome 11 and Moe2 on chromosome 19, that influence 
severity of the Q54 phenotype (18). Fine mapping of Moe2 identified Kcnv2 as a strong 
candidate gene (19). Transgenic transfer of the modified phenotype in vivo supported the 
identification of Kcnv2 as a modifier gene in mice (20). Discovery of two novel human 
KCNV2 mutations in pediatric epilepsy patients suggested that KCNV2 may also 
contribute to human epilepsy susceptibility (20). 
In this study, we generated interval-specific congenic (ISC) lines to confirm and 
fine map the Moe1 locus on chromosome 11. Our results indicated the Moe1 locus is 
complex with at least two modifiers in the interval that exhibit sex-specific effects. We 
then used an RNA-Seq approach for candidate gene analysis within the Moe1 sub-
intervals. Moe1 RNA-Seq data revealed numerous transcriptome differences and coding 
single-nucleotide polymorphisms (SNPs) between sex and strain. We further evaluated 
and prioritized candidate modifier genes that may contribute to strain-dependent 
differences in seizure susceptibility in Q54 mice. 
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Materials and Methods 
 
Mice 
Q54 transgenic mice [Tg(Eno2-Scn2a1*)Q54Mm] were generated as previously 
described (17). The Q54 line congenic on the B6 strain (B6.Q54) was established as 
described and is maintained by continued backcrossing of B6.Q54 hemizygous males to 
B6 females (Jackson Labs stock #000664) (18). Mice were group-housed with access to 
food and water ad libitum. All studies were approved by the Vanderbilt University 
Animal Care and Use Committees in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. 
 
Generation of ISC Lines 
Four ISC lines were generated carrying differing B6-derived chromosome 11 
segments within Moe1 on a congenic SJL background. B6 males were crossed with SJL 
females to create F1 progeny. Offspring from each generation were then continually 
backcrossed to SJL to generate congenic lines. Whole genome genotyping was performed 
at generations N2 and N5 using the mouse MMDAP 768 SNP panel on the Illumina 
GoldenGate Platform (Illumina, San Diego, CA, USA) (21). Animals retaining B6 alleles 
in Moe1 with the lowest percentage of B6 alleles in the rest of the genome were selected 
for breeding to the next generation. Once established, ISC strains were maintained by 
continued backcrossing to SJL and genotyping for chromosome 11 microsatellite (MIT) 
markers at all generations. All ISC lines were backcrossed for ≥10 generations prior to 
experiments. 
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Genotyping 
Mice were tail biopsied on postnatal day 14 and genotyped. DNA was prepared 
from tail biopsies by phenol:chloroform extraction and ethanol precipitation or using the 
Gentra Puregene Mouse Tail Kit according to the manufacturer's instructions (Qiagen, 
Valencia, CA, USA). The Q54 transgene was genotyped as previously described (18). 
ISC lines were genotyped for chromosome 11 MIT markers by polymerase chain reaction 
and analyzed on 2% agarose or 7% non-denaturing polyacrylamide gels. 
 
Phenotyping 
Chromosome 11 ISC females were crossed with hemizygous B6.Q54 males to 
generate (B6.Q54 × ISC.SJL).F1 offspring (F1.Q54) carrying heterozygous or 
homozygous B6 alleles in Moe1. We used a similar phenotyping paradigm used for low-
resolution mapping of the Moe1 locus (18). Briefly, F1.Q54 offspring underwent 30 
minute video-taped observations at three and six weeks of age. All observation sessions 
occurred between 1:00 PM and 4:00 PM. On the basis of prior extensive video-
electroencephalogram monitoring, spontaneous behavioral seizures were assessed offline 
by a blinded observer using Observer XT software (Noldus, Wageningen, Netherlands) 
(17). We counted the number of visible focal motor seizures with forelimb clonus and 
repetitive movements lasting one to five seconds (Racine seizure scale 3) (22). Seizure 
counts from the three and six week observations were combined to obtain a frequency of 
seizures in 60 minutes for each animal. 
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Statistical Analysis 
Average seizure frequencies were compared between ISC lines and controls by 
analysis of variance (ANOVA) with Fisher's protected least significant difference 
(PLSD) post hoc test (n ≥ 9 per group). Outlier analysis was performed and subjects with 
seizure frequencies two standard deviations above and below the mean at three or six 
weeks of age were removed. Mice with missing three or six week data due to outlier 
frequencies or death were not included in the study. Preliminary analysis indicated that 
males and females differed within the strains. Therefore, male and female data were 
analyzed separately. Survival was assessed until 12 weeks of age using Kaplan-Meier 
analysis with P-values reported from Logrank Mantel-Cox. 
 
RNA Isolation 
Total RNA was isolated from whole brains of six week old B6 or SJL male and 
female mice with the TRIzol reagent according to the manufacturer's instructions 
(Invitrogen, Carlsbad, CA, USA). RNA integrity was assessed on an Agilent 2100 
Bioanalyzer (Agilent, Santa Clara, CA, USA) and all samples received RNA integrity 
numbers (RIN) of ≥8.20. For each group, total RNAs from four mice were combined to 
generate a pooled sample. 
 
Sample Preparation for RNA-Seq 
Starting with three µg of total RNA, samples underwent poly-A selection, 
chemical fragmentation and first and second strand cDNA synthesis using the TruSeq 
RNA sample preparation kit (Illumina, San Diego, CA, USA). Following second strand 
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cDNA synthesis, samples were prepared for sequencing on the Illumina HiSeq 2000 
platform in the Vanderbilt Technologies for Advanced Genomics Core (http://vantage. 
vanderbilt.edu) according to standard methods (23). Two multiplexed lanes of 100-bp 
single-end sequencing were performed, resulting in 75 million mappable reads per lane. 
 
RNA-Seq Data Analysis 
Base calling and filtering of sequence reads were performed with the Illumina 
pipeline (23). Subsequent analysis was performed using Tuxedo Tools on the open, web-
based platform GALAXY (24-26). Tophat aligned RNA-Seq reads to the mm9 genome 
using Bowtie, allowing reads that span exon–exon boundaries to be aligned to the correct 
genomic location. Following alignment, novel splice variants were identified (27-29). 
Cufflinks assembled transcripts, estimated abundance in fragments per kilobase of exon 
per million fragments mapped (FPKM) and tested for differential expression and 
regulation. Cuffcompare combined Cufflink transcript data across sex and strain. Cuffdiff 
tested for statistically significant differences in total gene and transcript expression, 
splicing, transcription start sites (TSS) and promoter usage (30-32). Parameter settings 
for each analysis tool are detailed in Table 2.1. 
Variant calls were performed by the Vanderbilt Computational Genomics Core 
using the Genome Analysis Toolkit for SNP discovery (http://www.broadinstitute.org/ 
gsa/wiki/index.php/Main_Page). Quality filtering retained SNPs with a Phred score of 
>Q20. Additional manual filtering removed the following: SNPs that were different 
between male and female of the same strain, heterozygous or groups with missing sample 
data. SNPs that were homozygous alternate from the B6 reference genome were retained. 
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Variant call format (VCF) files were uploaded to Ensembl's Variant Effect Predictor to 
reveal the functional consequences of identified variants (33). Non-synonymous amino 
acid substitutions were uploaded to sift (http://sift.jcvi.org/) to predict the potential 
impact on protein function (34). 
 
Table 2.1 Parameter Settings for GALAXY RNA-Seq Analysis 
RNA-Seq analysis was performed by GALAXY using the following parameters. RNA-Seq reads were 
aligned by Tophat to the mm9 genome by Bowtie. Cufflinks assembled transcripts, estimated abundance in 
FPKM and tested for differential expression and regulation. Cuffcompare combined Cufflinks transcript 
data across sex and strain. Cuffdiff tested for statistically significant differences in total gene and transcript 
expression, splicing, TSS and promoter usage. 
 
Tool Parameter Setting 
Tophat 
(V. 1.1.2) 
Anchor length 8 
Max. number of mismatches in the anchor region of spliced alignment 0 
Min. intron length 70 
Max. intron length 500000 
Allow indel search Yes 
Max insertion length 3 
Max deletion length 3 
Max. number of alignments allowed 20 
Min. intron length found during split-segment (default) search 50 
Max. intron length found during split-segment (default) search 500000 
Number of mismatches allowed in the initial read mapping  2 
Number of mismatches allowed in each segment alignment for reads mapped  2 
Min. length of read segments 25 
Use own junctions No 
Use closure search No 
Use coverage search Yes 
Min. intron length that may be found during coverage search 50 
Max. intron length that may be found during coverage search 20000 
Use microexon search No 
Cufflinks 
(V. 0.0.5) 
Max. intron length 300000 
Min. isoform fraction 0.1 
Pre MRNA fraction 0.15 
Perform quartile normalization No 
Use reference annotation Yes 
Perform bias correction No 
Set parameters for paired-end reads No 
Cuff-
compare 
(V. 0.0.5) 
Use reference annotation Yes 
Use sequence data Yes 
Choose the source for the reference list Local 
Cuffdiff 
(V. 0.0.5) 
Perform replicate analysis No 
False discovery rate 0.05 
Min.  alignment count 1000 
Perform quartile normalization No 
Perform bias correction No 
Set parameters for paired-end reads No 
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Results 
 
Interval-Specific Congenics 
We previously mapped the Q54 modifier Moe1 to mouse chromosome 11 with a 
peak at D11MIT289 (95 Mb) (18). Inheritance of an SJL allele at this locus conferred 
increased seizure resistance, while homozygosity for B6 alleles conferred increased 
susceptibility. To confirm the initial mapping results and refine the Moe1 interval, we 
generated four ISC lines. Each line contained varying B6-derived chromosome 11 
segments within the Moe1 1 LOD support interval on a congenic SJL background. ISC 
lines are represented by their MIT marker location. The resulting ISC lines were as 
follows: ISC-A (D11Mit33-D11Mit58, 81–104 Mb); ISC-B (D11Mit33-D11Mit122, 81–
93 Mb); ISC-C (D11Mit122-D11Mit58, 93–104 Mb); ISC-D (D11Mit284-D11Mit58, 
89–104 Mb) (Figure 2.1). 
 
 
Figure 2.1 Fine Mapping of Moe1 with ISC Lines 
ISC lines were generated with varying B6-derived chromosome 11 segments (colors) on an SJL 
background (white). MIT markers used for ISC generation are identified along the chromosome. The 
original mapping for epilepsy susceptibility localized the Moe1 peak to D11Mit289.  
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ISC Phenotyping 
Chromosome 11 ISC females were crossed with B6.Q54 males to generate 
F1.Q54. Offspring were heterozygous or homozygous for B6 alleles in Moe1 (Figure 
2.2). Genotypes for the F1 generation were obtained at the expected Mendelian ratios. 
F1.Q54 offspring underwent 30 minute video-taped observations for visible spontaneous 
focal motor seizures at three and six weeks of age. Average seizure frequencies (# 
seizures/60 minutes) were compared between ISC groups carrying homozygous B6 
alleles and controls carrying heterozygous alleles. Preliminary analysis indicated within-
strain sex differences suggesting the possibility of sex-specific modifier effects. 
 
 
 
Figure 2.2 ISC Phenotyping Paradigm 
ISC lines were crossed with B6.Q54, generating F1.Q54 offspring. F1.Q54 mice will be heterozygous or 
homozygous for B6 alleles in Moe1. 
 
A significant difference in seizure frequency was identified between ISC males 
and controls by ANOVA (F4,70 = 3.321, p < 0.015). Male mice carrying homozygous B6 
alleles in the ISC-D interval (89–104 Mb) exhibited more seizures than heterozygous 
control littermates (p < 0.003) (Figure 2.3). Interestingly, males with homozygous B6 
alleles in the ISC-C interval (93-104 Mb) showed no difference compared to 
heterozygous control littermates (p > 0.496) (Figure 2.3). This suggests that the small 
B6
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Chr 11 Chr 11
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region of non-overlap between ISC-C and ISC-D (D–C; 89–93 Mb) is likely responsible 
for increased seizure frequency in males. 
 
 
Figure 2.3 Seizure Frequency in ISC Males 
Average number of seizures in 60 minutes for each genotype group is shown. Significant differences 
between genotype groups were determined by ANOVA: F4,70= 3.321, p < 0.015 with significant p-values 
determined by Fishers PLSD post hoc test. Data are represented as mean ± SEM.  
 
A significant difference in seizure frequency was identified between ISC females 
and controls by ANOVA (F4,70 = 2.601, p < 0.043). Female mice carrying homozygous 
B6 alleles in the ISC-C interval (93–104 Mb) exhibited more seizures than heterozygous 
control littermates (p < 0.047) (Figure 2.4). This suggests that B6 homozygosity in the 
distal Moe1 interval is permissive in females. Surprisingly, females with homozygous B6 
alleles in the ISC-D interval (89–104 Mb) showed no difference in seizure frequency 
compared to heterozygous control littermates (p > 0.805). This suggests the male 
0
5
10
15
20
25
30
35
40
BS A B C D
A
v
er
a
g
e 
#
 o
f 
se
iz
u
re
s 
in
 6
0
 m
in
p< 0.003
p < 0.002
p < 0.014
p < 0.048
(n=25) (n=9) (n=17) (n=12) (n=12)
40 
 
modifier located in the small region of non-overlap between ISC-C and ISC-D (D–C; 89–
93 Mb) may mask the effect of the distal permissive modifier in females. 
 
 
Figure 2.4 Seizure Frequency in ISC Females 
Average number of seizures in 60 minutes for each genotype group is shown. Significant differences 
between genotype groups were determined by ANOVA: F4,70= 2.601, p < 0.043 with significant p-values 
determined by Fishers PLSD post hoc test. Data are represented as mean ± SEM.  
 
 
In both sexes, B6 homozygosity in the large ISC-A region (81–104 Mb) that 
spans the entire Moe1 1 LOD support interval did not result in significant differences in 
seizure frequency compared to heterozygous controls (Males: p > 0.312; Females: p > 
0.097). This suggests that multiple modifiers lie within Moe1. B6 homozygosity in the 
proximal region of the Moe1 interval may mask the effect of more distal permissive 
modifiers in both males and females. However, B6 homozygosity in the small ISC-B 
proximal interval (81–93 Mb) alone does not significantly reduce seizure frequency 
compared to heterozygous controls (Males: p > 0.713; Females: p > 0.201). 
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ISC x B6.Q54 Survival 
 We also determined the effect of ISC regions on lifespan in the F1.Q54 offspring 
generated by crossing ISC-A, B, C and D lines with B6.Q54. Following seizure analysis 
described above, F1.Q54 mice were monitored for survival to 12 weeks of age. We 
compared survival between F1.Q54 mice carrying B6 alleles in the ISC intervals with 
control heterozygous littermates using Kaplan Meier analysis. Survival to 12 weeks of 
age was significantly altered in females. Female mice carrying homozygous B6 alleles in 
the ISC-A interval had significantly reduced survival compared to heterozygous control 
littermates (p < 0.004) and ISC-B females (p < 0.007) (Figure 2.5, dashed). There was no 
significant difference in survival identified in males (Figure 2.5, solid). Within genotype 
groups there were sex-specific significant differences in survival. Among mice with 
homozygous B6 alleles in ISC-A, males lived significantly longer than females (p < 
0.009) (Figure 2.5). 
 
 
Figure 2.5 Kaplan Meier Survival Plot of ISC and Control Lines 
F1.Q54 ISC-A, B, C, D and control heterozygous littermates were monitored until 12 weeks of age. ISC-A 
females live significantly shorter lives than control littermates (p < 0.004) and ISC-B females (p < 0.007). 
When comparing across sex, ISC-A males live significantly longer than ISC-A females (p < 0.009). 
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Candidate Gene Analysis by RNA-Seq 
Due to the complexity of the Moe1 interval and the high gene density of 
chromosome 11, we performed sequence-based transcriptome analysis in order to 
identify candidate modifier genes in Moe1. Focused analysis of Moe1 revealed numerous 
significant differences in total gene and transcript expression, TSS, alternate promoter 
usage and splicing (Table 2.2). Our ISC results indicated that B6 homozygosity in the D–
C interval (89–93 Mb) increased seizure frequency in males. Within the D–C interval, 
RNA-Seq identified three genes with significant gene or transcript expression differences 
between B6 and SJL males. On the basis of our female ISC experiments, B6 
homozygosity in the ISC-C interval (93–104 Mb) increased seizure frequency. In the 
ISC-C region, RNA-Seq analysis revealed 32 genes with significant gene or transcript 
expression differences between B6 and SJL females. A complete list of significant 
differences in the Moe1 region by RNA-Seq is provided in Table 2.2. 
 
Table 2.2 Significant Differences in the Moe1 Interval Via RNA-Seq 
Grey shading indicates a significant difference; Open boxes indicate no difference. Abbreviations are as 
follows: B = C57BL/6J, S = SJL/J, M = Male, F= Female. 
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Table 2.2 (Cont.) Significant Differences in the Moe1 Interval Via RNA-Seq 
Grey shading indicates a significant difference; Open boxes indicate no difference. Abbreviations are as 
follows: B = C57BL/6J, S = SJL/J, M = Male, F= Female. 
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Table 2.2 (Cont.) Significant Differences in the Moe1 Interval Via RNA-Seq 
Grey shading indicates a significant difference; Open boxes indicate no difference. Abbreviations are as 
follows: B = C57BL/6J, S = SJL/J, M = Male, F= Female. 
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Table 2.2 (Cont.) Significant Differences in the Moe1 Interval Via RNA-Seq 
Grey shading indicates a significant difference; Open boxes indicate no difference. Abbreviations are as 
follows: B = C57BL/6J, S = SJL/J, M = Male, F= Female. 
 
 
 
 
To further evaluate candidate genes, we performed SNP analysis to identify genes 
with coding sequence polymorphisms between B6 and SJL. In region D–C (89–93 Mb), 
which contains 26 known and predicted genes, we identified 25 SNPs, including two 
non-synonymous (NS) SNPs in the gene Tom1l1. In interval C (93–104 Mb), which 
contains 534 known and predicted genes, we identified 630 SNPs, including 29 NS SNPs 
in 22 genes. The complete list of NS-coding polymorphisms in Moe1 and the predicted 
impact on protein function are provided in Table 2.3. 
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Table 2.3 Non-Synonymous Coding SNPS in Moe1 
SNPs were uploaded to Ensembl’s variant call predictor to reveal functional consequences of variants. NS 
amino acid substitutions were uploaded to SIFT to predict the potential impact on protein function. 
 
 
Interval Gene Location
Amino 
Acid 
Change SNP RS # Sift Prediction
Zfp830 11:82578439 R/K aGg/aAg TOLERATED with a score of 0.95
Lig3 11:82604104 R/S agG/agT rs28225588 TOLERATED with a score of 1
Lig3 11:82609212 K/R aAa/aGa rs28225573 TOLERATED with a score of 0.26
Lig3 11:82610931 V/D gTt/gAt rs28225563  TOLERATED with a score of 1
Lig3 11:82613102 N/S aAt/aGt rs28225556  TOLERATED with a score of 1
Rad51i3 11:82695305 V/A gTc/gCc rs28209138 AFFECT PROTEIN FUNCTION with a score of 0.02
Nle1 11:82718877 V/I Gtt/Att rs13468707  TOLERATED with a score of 1
Dusp14 11:83862583 W/R Tgg/Cgg rs13459132 TOLERATED with a score of 0.59
Ints2 11:86031421 M/I atG/atA rs29431276 TOLERATED with a score of 0.07
Ints2 11:86064535 R/H cGt/cAt rs29420094 TOLERATED with a score of 1
Tubd1 11:86374767 T/S Aca/Tca rs27026986 TOLERATED with a score of 0.96
Bzrap1 11:87575147 G/R Ggg/Agg rs51462366 TOLERATED with a score of 0.64
Bzrap1 11:87589796 M/L Atg/Ctg rs28278310 TOLERATED with a score of 0.34
Bzrap1 11:87591464 A/S Gcg/Tcg rs28278307 TOLERATED with a score of 0.75
Lpo 11:87623710 Y/S tAc/tCc rs13472575 TOLERATED with a score of 0.46 
Mks1 11:87670369 K/R aAg/aGg rs51587946  TOLERATED with a score of 1
Vezf1 11:87886991 S/A Tca/Gca rs29434284 TOLERATED with a score of 0.89
Cuedc1 11:87998174 N/Y Aat/Tat rs28240982 TOLERATED with a score of 0.07
Akap1 11:88705691 M/I atG/atC rs29403244 TOLERATED with a score of 0.21
Akap1 11:88706130 T/I aCc/aTc rs27116277 TOLERATED with a score of 0.06
Akap1 11:88706174 F/L ttT/ttG rs27116276 TOLERATED with a score of 0.75
Akap1 11:88706910 C/S tGt/tCt rs27116275 TOLERATED with a score of 0.84
Coil 11:88842523 L/S tTg/tCg rs29403395 TOLERATED with a score of 0.92
Coil 11:88843369 G/D gGc/gAc AFFECT PROTEIN FUNCTION with a score of 0.03
Tom1l1 aCt/aTt rs13469307 TOLERATED with a score of 0.27
Tom1l1 gCt/gGt rs13469308 TOLERATED with a score of 0.08
Samd14 11:94886027 N/H Aac/Cac rs27101631 TOLERATED with a score of 0.09
Ube2z 11:95926522 S/A Tcg/Gcg TOLERATED with a score of 0.38
Cdk5rap3 11:96770100 T/M aCg/aTg TOLERATED with a score of 0.10
Sp2 11:96822911 T/I aCc/aTc rs3708840 TOLERATED with a score of 0.62
Arhgap23 11:97309791 I/V Atc/Gtc rs45809946  TOLERATED with a score of 0.80
Cwc25 11:97614056 R/W Cgg/Tgg rs27089733 DAMAGING with a score of 0.01
Plxdc1 11:97802222 A/E gCg/gAg rs27073969 TOLERATED with a score of 0.31
Plxdc1 11:97817828 Q/R cAa/cGa rs27057105 TOLERATED with a score of 0.53
Nr1d1 11:98631530 R/Q cGg/cAg rs27041024 TOLERATED with a score of 0.29
Rapgefl1 11:98708468 R/P cGg/cCg TOLERATED with a score of 0.15
Top2a 11:98855618 P/L cCt/cTt TOLERATED with a score of 0.19
Top2a 11:98855703 T/A Act/Gct rs27025992 TOLERATED with a score of 0.61
Krt10 11:99250636 L/R cTa/cGa AFFECT PROTEIN FUNCTION with a score of 0.00
Fkbp10 11:100284113 G/S Ggc/Agc AFFECT PROTEIN FUNCTION with a score of 0.00
Nt5c3l 11:100291151 C/Y tGc/tAc TOLERATED with a score of 1
Nt5c3l 11:100291164 Y/H Tac/Cac rs29442152 TOLERATED with a score of 0.55
Nt5c3l 11:100301235 C/F tGt/tTt TOLERATED with a score of 0.72 
Cnp 11:100441755 D/G gAt/gGt AFFECT PROTEIN FUNCTION with a score of 0.03
Zfp385c 11:100490929 A/T Gct/Act rs27090504 TOLERATED with a score of 0.47
Ramp2 11:101107793 P/T Ccg/Acg TOLERATED with a score of 0.25
Wnk4 11:101136570 A/S Gct/Tct rs52181149  TOLERATED with a score of 1
Aarsd1 11:101278496 S/N aGc/aAc rs13468999 TOLERATED with a score of 0.51
Rundc1 11:101292783 V/A gTg/gCg rs27057199 TOLERATED with a score of 0.59
Rundc1 11:101294928 H/P cAc/cCc TOLERATED with a score of 1 
Rundc1 11:101295155 L/I Ctt/Att rs6402514  TOLERATED with a score of 1
Rundc1 11:101295452 V/M Gtg/Atg TOLERATED with a score of 0.07 
Etv4 11:101632794 I/F Att/Ttt rs28234792 TOLERATED with a score of 0.71
Tmub2 11:102149413 S/N aGc/aAc rs29484653 TOLERATED with a score of 0.49
Adam11 11:102634721 Q/K Cag/Aag TOLERATED with a score of 0.91
B
D-C
C
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Following RNA-Seq analysis, we prioritized candidate genes based on the ISC 
mapping results, consideration of gene function, location and timing of expression and 
prior evidence of involvement in neuronal hyperexcitability (Table 2.4). Top candidate 
modifier genes were identified as Hlf in males and Cacna1g and Cacnb1 in females. 
 
Table 2.4 Top Candidate Modifier Genes in Moe1 
†
Priority rating is based on biological function and prior association with neuronal hyperexcitability 
phenotypes. *** highest priority; **moderate priority; *low priority. 
 
Interval Priority
†
 Gene Symbol Gene Name 
B 
* Cltc Clathrin 
* Dynll2 Dynein Light Chain 2 
D-C *** Hlf Hepatic Leukemia Factor 
C 
*** Cacna1g Voltage-Dep. Ca
2+
 Channel,  T type, α1G 
*** Cacnb1 Voltage-Dep. Ca
2+
 Channel, β1 
** Slc25a39 Solute Carrier Family 25, Member 39 
* Pnpo Pyridoxine 5'-Phosphate Oxidase 
* Hap1 Huntingtin-Associated Protein 1 
 
 
In the D–C interval (89–93 Mb) that contains the male-specific modifier, there 
were significant expression differences between B6 and SJL males in two genes, Hlf 
(hepatic leukemia factor) and Stxbp4 (syntaxin binding protein 4) and a processed 
pseudogene, GM11512. Stxbp4 functions in the insulin receptor signaling pathway and 
glucose transport (35). Currently, there is no evidence linking Stxbp4 to neuronal 
hyperexcitability. Hlf is a member of the proline and acidic amino acid-rich basic leucine 
zipper (PAR bZIP) transcription factor family which has previously been linked to 
epilepsy (36). A significant difference in a Hlf transcript was only identified between B6 
48 
 
and SJL males, consistent with a male-specific effect (Figure 2.6). Taken together, this 
suggests that Hlf is a strong candidate modifier gene in males (Table 2.4). 
 
 
Figure 2.6 Expression of Hlf-002 Transcript in B6 and SJL Brain 
The RNA-Seq FPKM values and confidence interval for each group is shown. Boxes represent the range of 
values and whiskers represent the 95% confidence interval calculated by Cuffdiff. Q-values are false 
discovery rate-adjusted p-values (Hlf-002= ENSMUST00000043658). 
 
 
The ISC-C interval (93–104 Mb) which harbors a female-specific modifier 
contains numerous genes with expression differences between B6 and SJL females. Of 
the five genes with a total gene expression difference between females, three are involved 
in basic cellular processes and two have unknown function. RNA-Seq identified 32 genes 
with significant differences in transcript expression. A large fraction of these genes are 
involved in basic cellular processes, with no direct evidence connecting them to neuronal 
hyperexcitability. There was a significant strain difference in transcript expression of 
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Slc25a39, which is a member of the mitochondrial solute carrier family 25 (SLC25) (37). 
A family-based study of epilepsy with suggestive linkage to chromosome 17q12-24 
showed differential expression of SLC25A39 in affected family members (38). However, 
sequencing did not reveal a pathogenic variant in this gene. On the basis of its tenuous 
association with epilepsy, Slc25a39 was retained as candidate modifier gene with lower 
priority (Table 2.4). 
Cacna1g and Cacnb1 emerged as top candidate modifier genes in females based 
on their direct connection to epilepsy and the strong association between ion channels 
and epilepsy. Human mutations in both genes have been identified in epilepsy patients 
(39-41). Differences in five major Cacna1g transcripts were identified between B6 and 
SJL females (Figure 2.7). These transcripts, differing in splicing of exons 14, 25 and 26, 
have known differences in gating, kinetics and voltage dependencies (42-44). There were 
also several significant differences in promoter usage, TSS and splice variants between 
sex and strain. A Cacnb1 female-specific difference was identified between B6 and SJL 
in transcript Cacnb1-006, a processed transcript that is not translated (Figure 2.8). There 
were also several significant differences in promoter usage, TSS and splice variants 
between sex and strain. 
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Figure 2.7 Differential Expression of Cacna1g Alternatively Spliced Transcripts 
Inclusion/exclusion of cassette exons 14 and 26 and alternate splicing of exon 25 are shown for the five 
transcripts that exhibited significant differences between B6 and SJL females. The location of alternatively 
spliced exons are shown on the Cacna1g channel protein (bottom). FPKM values and confidence intervals 
for B6 and SJL females are shown. Q-values are false discovery rate-adjusted p-values. 
 
 
 
Figure 2.8 Alternative Splicing and Differential Expression of Cacnb1 
A. Cacnb1 alternatively spliced transcripts are shown. Purple shaded boxes represent coding regions and 
blue shaded boxes are non-coding regions. B. Respective FPKM values and confidence intervals for B6 and 
SJL female transcripts are shown (*q < 0.02). Q-values are false discovery rate-adjusted p-values. 
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Discussion 
Genetic modifier loci influencing the Q54 epilepsy phenotype were initially 
mapped to chromosomes 11 (Moe1) and 19 (Moe2) in a backcross between B6 and SJL 
strains (18). We constructed ISC strains to confirm the presence of Moe1 on chromosome 
11 and refine the critical interval. Our results revealed that the interval likely contains 
multiple modifiers that contribute to phenotype severity of Q54 mice. Sex specific 
modifiers were also identified within the interval. Similar to our results, previous studies 
of epilepsy quantitative trait loci (QTL) in polygenic mouse models have shown that the 
substructure of QTL can be complex with multiple genes contributing to the low-
resolution mapping peak (14, 45). 
In females, B6 homozygosity in the ISC-C interval conferred increased seizure 
frequency, suggesting the presence of a permissive modifier gene in this interval. The 
large ISC-A region that spans the entire Moe1 1 LOD support interval resulted in females 
with near-significant differences in seizure frequency (p > 0.097) and reduced survival (p 
< 0.004) compared to heterozygous controls. This suggests that significant differences in 
seizure frequency in ISC-A would likely result if more females were added to the study. 
Significant seizure frequency differences in ISC-A further supports Moe1 as a modifier 
locus of the Q54 phenotype. 
In males, increased seizure frequency was associated with B6 homozygosity in 
the ISC-D interval but not in the ISC-C interval. This suggests that a male-specific 
permissive modifier is located in the small non-overlapping interval between ISC-C and 
ISC-D (D–C; 89–93 Mb). Interestingly, ISC-A males did not experience significant 
differences in seizure frequency compared to heterozygous controls (p > 0.312). This 
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suggests that multiple modifiers lie within Moe1 which affect the male Q54 phenotype. 
B6 homozygosity in the proximal region of the Moe1 interval may mask the effect of 
more distal permissive modifiers in males. However, B6 homozygosity in the small ISC-
B proximal interval (81–93 Mb) alone does not significantly reduce male seizure 
frequency compared to heterozygous controls (p > 0.713). 
Utilizing RNA-Seq, we were able to identify a significant number of transcripts 
that exhibited within-strain sex differences throughout the Moe1 interval. These 
differences likely result from multiple different causes, which may include brain sexual 
dimorphism, epigenetics and endocrine influences. 
Combined ISC line seizure data and RNA-Seq analysis identified several strong 
candidate modifiers that may contribute to severity of the Q54 seizure phenotype. Top 
candidate modifier genes include Cacna1g and Cacnb1 in females and Hlf in males. 
Although we identified significant transcript differences in Cacna1g, Cacnb1 and Hlf, we 
did not identify SNPs within the coding regions. It is likely that non-coding SNPs 
contribute to the observed transcript differences. Future sequencing of the non-coding 
regions of Cacna1g, Cacnb1 and Hlf will determine the contribution of non-coding SNPs. 
Cacna1g is a T-type calcium (Ca
2+
) channel α1 subunit which propagates low-
voltage activated (LVA) Ca
2+
 currents (46). T-type channels regulate neuronal firing by 
conducting Ca
2+
 during action potentials and can switch neurons between firing modes 
(47). T-type channels are expressed at high densities on thalamic neurons. These neurons 
innately oscillate during sleep, but can also inappropriately oscillate and cause a 
generalized seizure (48, 49). Rapid activation of T-type channels is responsible for the 
generation of low-threshold spikes, which trigger epileptic ‘burst-firing’ patterns. It is 
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also responsible for abnormal spike-wave discharges (SWDs) in absence epilepsy that 
arise from synchronous firing of thalamocortical networks (50-52). Several spontaneous 
mouse models of absence epilepsy, including lethargic, tottering and stargazer, exhibit 
abnormalities in LVA Ca
2+
 currents, likely resulting in abnormal thalamocortical 
synchronization and absence epilepsy in the mutant animals (53). Deletion of Cacna1g in 
mice suppressed GABAB receptor agonist-induced SWDs, indicating an essential role for 
this gene in seizure expression (52, 54). In humans, SNPs in CACNA1G have been 
associated with idiopathic generalized epilepsy (41). 
Our RNA-Seq analysis identified expression, TSS, promoter usage and splicing 
differences in Cacna1g between sex and strain. Alternative splicing of T-type Ca
2+
 
channels is known to contribute to their functional diversity. We identified significant 
strain differences between females in the expression of five major Cacna1g transcripts 
with known functional diversity. The inclusion of cassette exon 14 has been shown to 
shift steady-state inactivation in the hyperpolarized direction and accelerate activation 
and inactivation kinetics (42, 43). Inclusion of cassette exon 26 contributes to more 
hyperpolarized steady-state inactivation and slower recovery from inactivation (42). Exon 
25 has an internal donor site, resulting in a short exon 25 (B) or full length (A) (Figure 
2.7) (42-44, 55). Transcripts with the 25A exon activate and inactivate at more 
hyperpolarized potentials, while 25B exon transcripts have slower activation and 
inactivation kinetics (42). On the basis of this information, transcripts that exhibit 
significantly higher expression in SJL females have the most hyperpolarized steady-state 
inactivation potential and the fastest activation and inactivation kinetics (Figure 2.7). We 
hypothesize that SJL females have a higher portion of Cacna1g channels that activate 
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quickly, but inactivate rapidly and prematurely. This early inactivation state may lead to a 
low probability for neurons to reach synchronous oscillations, a common feature of 
epilepsy (50-52). Conversely, transcripts expressed at higher levels in B6 females 
compared to SJL are those with depolarized steady-state inactivation potentials and 
slower rates of activation and inactivation (Figure 2.7) (42). We hypothesize B6 females 
have an increased number of Cacna1g channels that are prone to hyperexcitability. This 
hyperexcitability emerges from an altered window current, resulting from inactivation 
shifts and rate changes, a known contributor to epilepsy (56). 
Cacnb1 encodes one of four homologous Ca
2+
 channel β subunits. β subunits 
modulate α1 channel trafficking, gating and kinetics (57-59). Cacnb1 has four splice 
variants, which are highly expressed in the hippocampus and dentate gyrus (57, 58). β 
subunits have been previously linked to epilepsy in mice. Lethargic mice have a mutation 
in Cacnb4 that results in absence epilepsy, severe ataxia and loss of motor coordination 
(39, 60). In humans, surgical resection samples from temporal lobe epilepsy patients 
exhibited an upregulation of CACNB1 and CACNB2 (59). It was hypothesized that the 
increased expression may underlie enhanced Ca
2+
 currents commonly seen in rodent 
kindling and kainate models of temporal lobe epilepsy (59, 61-63). CACNB1 mutations 
have been identified in patients with a history of febrile seizures, juvenile myoclonic 
epilepsy, episodic ataxia, generalized epilepsy and praxis-induced seizures (39, 40).  
RNA-Seq analysis determined that SJL females express significantly higher levels 
of transcript Cacnb1-006 than B6 females (Figure 2.8). Although this transcript does not 
contain an open reading frame, it does undergo post-transcriptional processing, 
suggesting the possibility that it may act as a long non-coding RNA (lncRNA). Recent 
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evidence shows the importance of non-coding RNAs (ncRNA) in the brain (64-68). 
ncRNAs have been shown to contribute to neural differentiation and cell identity, 
hippocampal development, oligodendrocyte myelination and synaptic plasticity (69). 
Additionally, lncRNAs have been implicated in neurodevelopmental, neurodegenerative, 
neuroimmunological and psychiatric disorders and, relevant to our studies, epilepsy (69). 
Mice deficient in the lncRNA Evf2 had reduced numbers of GABAergic interneurons in 
the hippocampal formation and displayed reduced synaptic inhibition (70). This suggests 
the importance of a lncRNA in the formation of GABA circuitry and suggests a potential 
mechanism for hyperexcitability. The lncRNA BC1 has also been implicated in a seizure 
phenotype. BC1
KO/KO
 homozygous knockout mice exhibited audiogenic seizures and it is 
hypothesized that BC1 lncRNA modulates hyperexcitability via the metabotropic 
glutamate receptor pathway (71). It is possible that the Cacnb1-006 transcript may act as 
an lncRNA that directly or indirectly influences neuronal excitability. 
Hlf is a member of the PAR bZIP transcription factor family. The loss of the PAR 
bZIP transcription factor family (Hlf, Dbp and Tef) results in mice with spontaneous, 
generalized tonic-clonic and absence seizures (36). Microarray expression analysis 
performed to investigate contributors to the PAR bZIP knockout epilepsy phenotype, 
revealed a twofold reduction in pyridoxal kinase (PDXK). PDXK encodes a coenzyme 
involved in the conversion of pyridoxine to pyridoxal 5′-phosphate (PLP), a key 
coenzyme involved in amino acid and neurotransmitter metabolism (36, 72). Mice 
defective in PLP metabolism experience fatal seizures, found to be a consequence of 
significantly reduced GABA levels (73). Mice maintained on a pyridoxine deficient diet, 
resulting in reduced PLP levels, experienced increased audiogenic seizures (74-76). 
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Human pyridoxine-dependent epilepsies can be successfully treated with PLP (77). Our 
RNA-Seq analysis showed that B6 males have a significant reduction in Hlf expression 
compared to SJL males (Figure 2.6). Reduced expression of Hlf in B6 males may lead to 
reduced PDXK and PLP levels and increased seizure susceptibility. Future studies testing 
the effect of pyridoxine deficiency on B6.Q54 mice may help determine the contribution 
of this pathway to Q54 epilepsy severity. 
On the basis of our ISC and RNA-Seq data, along with further analysis of gene 
function and association with seizures, we nominate Cacna1g, Cacnb1 and Hlf as strong 
functional candidates for Moe1. Future testing of high priority candidate genes will be 
necessary to determine if they contribute to the epilepsy severity of Q54 mice. 
Understanding the molecular basis of genetic modifiers in a mouse model can provide 
insight into human epilepsy. It has the potential to advance molecular diagnostic 
capabilities and identify novel therapeutic targets for the improved treatment of patients. 
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CHAPTER III 
 
VALIDATION OF CACNA1G AND HLF AS GENETIC MODIFIERS OF THE 
SCN2A
Q54
 EPILEPSY PHENOTYPE  
 
Introduction 
 Epilepsy is a common neurological disorder affecting approximately 3 million 
people in the United States (1). Nearly 900 mutations identified in voltage-gated sodium 
channel genes result in several types of human epilepsies, including Genetic Epilepsy 
with Febrile Seizures Plus (GEFS+), Benign Familial Neonatal-Infantile Seizures 
(BFNIS), Dravet and Ohtahara syndromes (2-4). Among affected family members who 
possess the same sodium channel mutation, the clinical severity of their disease can be 
strikingly different. This suggests that other factors, possibly genetic, must modify the 
primary mutation, resulting in a more or less severe phenotype.  
Several mouse models have been generated in order to study the genetic basis of 
epilepsy. A common feature found in these models is that the genetic strain background 
alters the disease phenotype, suggestive of genetic modifiers in epilepsy. The Scn2a
Q54
 
(Q54) transgenic mouse model has a gain-of-function mutation that results in persistent 
sodium current and epilepsy (5). On the C57BL/6J (B6) strain background, B6.Q54 mice 
have infrequent, adult-onset focal motor seizures and a 75% survival rate beyond six 
months of age (6). When crossed with the SJL/J (SJL) strain, the resulting F1.Q54 
generation experience high seizure frequency with juvenile onset and less than 25% 
survival until six months of age (6). We mapped two dominant loci that modify seizure 
susceptibility in Q54, designated Moe1 (Modifier of Epilepsy) on chromosome 11 and 
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Moe2, on chromosome 19 (6). Kcnv2 was identified as the modifier gene at Moe2 (7). 
Recent fine-mapping and RNA-Seq data suggested two sex-specific candidate modifier 
genes at the Moe1 locus, Cacna1g and Hlf in females and males, respectively (8).  
Cacna1g encodes the T-type calcium channel α1 subunit that propagates low-
voltage activated (LVA) calcium currents (9). Several mouse models that exhibit 
abnormalities in LVA calcium currents exhibit absence seizures and abnormal 
thalamocortical synchronization (10). Furthermore, single-nucleotide polymorphisms in 
human CACNA1G have been identified in patients with generalized epilepsy (11). 
Cacna1g has twelve identified alternative splice sites, resulting in numerous transcripts 
with distinct current properties (9, 12-15). Cacna1g is hypothesized to modify the Q54 
seizure phenotype through significant strain-specific differences in expression profiles of 
transcripts that have functional kinetic diversity in their LVA currents (8). SJL female 
mice preferentially express Cacna1g channels that reduce the likelihood of synchronous 
thalamocortical oscillations, a common feature of epilepsy (8, 16-18). In contrast, B6 
female mice express Cacna1g channels that are prone to hyperexcitability (8). 
Hlf encodes hepatic leukemia factor, a member of the PAR bZIP transcription 
factor family. Deletion of the PAR bZIP transcription factor family (Hlf, Dbp and Tef ) in 
a knock-out mouse model resulted in mice with spontaneous, generalized tonic-clonic 
and absence seizures (19). Microarray expression analysis was utilized to determine 
contributors to the epilepsy phenotype (19). A two-fold reduction in pyridoxal kinase 
(PDXK), a key enzyme involved in the conversion of pyridoxine to pyridoxal 5’ 
phosphate (PLP) was discovered (19). PLP is a key coenzyme involved in amino acid and 
neurotransmitter metabolism, including GABA and glutamate (Figure 3.1) (20). 
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Interestingly, PLP has a substantial connection to epilepsy. Pyridoxine-dependent 
epilepsies are successfully treated with PLP (21). Mice maintained on a pyridoxine 
deficient diet, consequently reducing PLP levels, experienced increased seizure 
frequency (22-24). Furthermore, mice defective in PLP metabolism experienced fatal 
seizures (25). Hlf is hypothesized to modify the Q54 seizure phenotype possibly by 
altering PDXK and PLP levels in a strain-dependent manner (Figure 3.1) (8). In males, 
B6 express Hlf at a significantly reduced level compared to SJL (8). A reduction in Hlf, 
with consequent reductions in PDXK and PLP levels, may be responsible for the 
increased seizure susceptibility seen in B6 males (8). 
 
 
Figure 3.1 The Pyridoxine Pathway 
Diagram illustrates the involvement of PDXK, PLP and pyridoxine in neurotransmitter metabolism (26). 
When the PAR bZIP family is knocked out, including Hlf, PDXK levels are reduced two-fold (19). 
Reprinted with permission (26). 
 
To determine the contribution of Cacna1g and Hlf to the seizure phenotype of 
Q54 mice, we utilized Cacna1g BAC transgenic and Hlf targeted knockout mouse 
models. We systematically evaluated the candidate modifier genes by testing their ability 
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to enhance or reduce severity of the Q54 seizure phenotype in double mutant mice. In 
addition to seizure analysis, we also evaluated our Hlf hypothesis by testing the effects of 
pyridoxine deficient and enriched diets on the Q54 phenotype. Furthermore, to determine 
whether Hlf would modify other types of epilepsy, we assessed the ability of Hlf to 
modify the Dravet phenotype of Scn1a
KO/+
 heterozygous knockout mice.  
 
Materials and Methods 
 
Mice 
A BAC clone containing Cacna1g (RP23-65I14) was obtained from BACPAC 
Resources (http://bacpac.chori.org/home.htm). BAC DNA was prepared with the 
NucleoBond BAC 100 kit, according to manufacturer’s instructions (Macherey-Nagel). 
DNA was reconstituted in polyamine injection buffer (27). Pronuclear injections into SJL 
fertilized oocytes were performed by the Vanderbilt University Transgenic Mouse/ESC 
Shared Resource. Injections resulted in a single Cacna1g BAC transgenic founder. The 
resulting strain, 1G5, is maintained on the SJL strain by continued backcrossing of 
hemizygous males to SJL females (Jackson Labs stock #000686).  
Hlf 
tm1Schb
 (Hlf 
KO/+
) targeted knockout embryos congenic on B6 were obtained 
from the European Mouse Mutant Archive (www.emmanet.org) (19). Fifty Hlf 
KO/+
 
heterozygous knockout embryos were implanted into pseudopregnant females at the 
Vanderbilt Transgenic Mouse/ESC Shared Resource. The Hlf 
KO/+
 heterozygous knockout 
line is maintained on the B6 strain by continued backcrossing of B6.Hlf 
KO/+
 males to B6 
females (Jackson Labs stock #000664). 
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Q54 transgenic mice [Tg(Eno2-Scn2a1*)Q54Mm] were generated as previously 
described (5). The B6.Q54
 
line is maintained on the B6 strain by continued backcrossing 
of hemizygous B6.Q54 males to B6 females (Jackson Labs stock #000664). Scn1a
tm1Kea
 
(Scn1a
KO/+
) heterozygous knockout mice were generated as previously described (28). 
The Scn1a
KO/+
 line is maintained on the 129S6/SvEvTac (129) strain by continued 
backcrossing of 129.Scn1a
KO/+
 males to 129 females (Taconic model #129SVE). 
Mice were group-housed with access to food and water ad libitum. All studies 
were approved by the Vanderbilt University Animal Care and Use Committees in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. 
 
Genotyping 
 Mice were tail biopsied on postnatal day 14 (P14) and genotyped. DNA was 
prepared from tail biopsies using the Gentra Puregene Mouse Tail Kit according to the 
manufacturer’s instructions (Qiagen). 1G5 transgenics were identified by using the 1G 
SP6 and 1G T7 primers indicated (Table 3.1). These primers amplify a 200 bp and 220 bp 
product, respectively. Hlf knockout mice were genotyped using primers designed to 
target the LacZ cassette. Primers LacZ R: 5’ATGTGAGCGAGTAACAACCCGTCGGA 
TCT, Hlf_LF: 5’CCCTTTTTCTTCTTCAGCATTTAG and Hlf_R: 5’GGATGCCATTC 
TCTGACAGG amplify a 200 bp wildtype product and a 400 bp knockout product. The 
Q54 transgene was genotyped as previously described (5). Scn1a
 
knockouts were 
genotyped as previously described (28). All genotyping was performed by PCR and 
analyzed on 2% agarose gels.  
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BAC Integrity, Copy Number and Expression  
 BAC integrity was evaluated in genomic DNA by PCR amplification of 
microsatellite and vector markers spanning the BAC (Table 3.1). SP6 and T7 vector 
markers flanked each end of the BAC construct, while D11VU microsatellite markers 
were located approximately every 32 Kb, including two within Cacna1g (Figure 3.2).  
To assess copy number, we used a Taqman assay as described previously by 
Chandler, et al (29). Quantitative PCR (qPCR) was performed using custom-designed 
Cacna1g and reference Scn5a Taqman assays described previously by Ernst, et al (Table 
3.1) (18). Genomic DNA from transgenic (n=17), homozygous transgenic (n=6) and 
control (n=8) littermates was used as template and a standard curve was applied to 
estimate copy number. Copy number standards were prepared by spiking SJL genomic 
DNA with BAC plasmid DNA equivalent to 0, 5, 10 and 20 copies per diploid genome. 
Transcript expression analysis was performed using Taqman gene expression 
assays (Applied Biosystems) (Table 3.1). RNA was extracted from whole brains of six 
week old transgenic (n=15), homozygous transgenic (n=7) and control (n=10) littermates 
using the RNeasy kit (Qiagen). Total RNA was then reverse transcribed using the 
SuperScript III First-Strand Synthesis System according to the manufacturer's 
instructions (Invitrogen). Samples were run in triplicate on an ABI 7900 HT and 
replicated over four plates. Relative transcript levels were assessed using the ∆∆CT 
method (30). Expression differences were compared between groups by ANOVA with 
Fisher’s PLSD post hoc tests. 
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Table 3.1 Primer Sequences for Cacna1g BAC Evaluation 
Evaluation of the BAC construct was completed through BAC integrity, copy number and expression 
analyses. BAC integrity was determined using the microsatellite markers indicated which spanned the 
entire BAC construct. Copy number was assessed by Taqman assay on genomic DNA. Expression analysis 
was performed on whole brain RNA using Taqman gene expression assays. 
 
 
 
Generation of Double Mutant Mice 
Cacna1g double mutant mice were generated by crossing SJL.1G5 females with 
B6.Q54 males. The resulting F1 generation had F1.1G5;Q54 mice and single mutant 
littermate controls at the expected Mendelian ratios.  
Hlf double mutant mice were generated on two background strains. First,     
B6.Hlf 
KO/+
 heterozygous females were crossed with B6.Q54 males to generate 
heterozygous B6.Hlf 
KO/+
;Q54 offspring. To produce animals for phenotyping 
experiments, B6.Hlf 
KO/+
;Q54 males were crossed with either B6.Hlf 
KO/+ 
or SJL females. 
Crossing B6.Hlf 
KO/+
;Q54 with B6.Hlf 
KO/+
 resulted in homozygous knockout,               
Hlf 
KO/KO
;Q54 and heterozygous knockout B6.Hlf 
KO/+
;Q54 test mice and control 
Primer Name Forward Sequence Reverse Sequence
D11VU2 TCCCATGGAGCATTGAAATC AGAGGAAGCTAGCCCCAGAG
D11VU3 TTTCCCGATCACCAAGAGAC GACCCTCAGCTAGGCAGTTG
D11VU5 CTGGATATTTCCCCCTGGAG CGGTTCTTCCAGGACAGGTA
D11VU8 TTCTGCCCTCCCAGAGATAA TCCTCAGGAGGGGATATCGT
D11VU11 TGATCCCCCTGCATAACACT TGGTGAGCCTCTGAAGGTTT
D11VU14 GAAGCAGCCAGGTTTCTCAC TTCCAGTGGCAAACACCATA
D11VU15 TTTACATTTTGACCAGCAAATAGC TCAGCCAGCCTAGTTGAACA
D11VU17 TACCCTTTGCCACGATAAGG GAGGCACTTCCAACCTTTCA
1G T7 TAATACGACTCACTATAGGG ATGGAGTGGACACATTGCAG
1G SP6 GATTTAGGTGACACTATAG TTCTAGGGACGTCAGGAAGC
Assay Name Forward / Taqman Assay Sequence Reverse Taqman Assay Sequence
Cacna1g TGGAACTGCCCATCATGAGAT CCTCATTCTGCTGTCCTGCTAAT
Scn5a AGGGTTTCTCTGTGACCCAAAC AGAGCTACGGGACACAGTATCCA
TaqM_Cacna1g
TaqM_Scn5a
Assay Name
Cacna1g
Tbp Mm00446971_m1
Taqman Assay
BAC Integrity
Copy Number
5'-6FAM-ATCACCGGTAAGGGAATGCATGCCAC-TAMRA-3'
5’-6FAM-CTTCCCCTACCCTTTTCCAGGCTCTCA-TAMRA-3
Expression
Mm00486571_m1 
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littermates. Offspring from this cross were not obtained at the expected Mendelian ratios 
(See Results section). Crossing B6.Hlf 
KO/+
;Q54 with SJL resulted in F1 double mutant 
F1.Hlf 
KO/+
;Q54 offspring and control F1.Q54 and F1.Hlf 
KO/+
 littermates that were 
obtained at the expected Mendelian ratios.  
To assess if Hlf was able to modify the Dravet phenotype of Scn1a
KO/+
 mice, 
B6.Hlf 
KO/+ 
females were crossed with 129.Scn1a
KO/+
 males. The resulting F1 generation 
produced double mutant F1.Hlf 
KO/+
;Scn1a
KO/+
 and single mutant littermate controls at the 
expected Mendelian ratios. 
 
 
Phenotyping 
Experimental mice were phenotyped as previously described (8). Briefly, 
littermates underwent 30 minute video-taped observations at three and six weeks of age. 
All observation sessions occurred between 1:00 PM and 4:00 PM. On the basis of prior 
extensive video-electroencephalogram monitoring, spontaneous behavioral seizures were 
assessed offline by a blinded observer using Observer XT software (Noldus) (5). We 
counted the number of visible focal motor seizures with forelimb clonus and repetitive 
movements lasting one to five seconds (Racine seizure scale 3) (31). Seizure counts from 
the three and six week observations were combined to obtain a frequency of seizures in 
60 minutes for each animal. Other seizure types, including generalized tonic-clonic 
seizures (GTCS), were also counted if observed. 
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Pyridoxine Deficient and Enriched Diets 
B6.Q54, F1.Q54, B6.Hlf 
KO/+
, B6.Hlf 
KO/KO
, B6.Hlf 
KO/KO
;Q54 and wildtype 
littermates were maintained on pyridoxine deficient (AIN-93G/No added pyridoxine), 
pyridoxine enriched (AIN-93G/8250 ppm added pyridoxine) or control (AIN-93G) diets 
(Purina Test Diet). At three weeks of age, mice were placed on the modified or control 
diet for six weeks. Animals were weighed and evaluated for general health once per 
week. At nine weeks of age, all mice underwent 30 minute video-taped observation to 
determine seizure frequency, as described above.  
 
Neurochemistry 
 A subset of mice maintained on the deficient or control diet were used for 
neurochemistry studies performed at nine weeks of age (n=4 for each genotype, sex and 
diet). Mice were deeply anesthetized with isoflurane, decapitated and forebrain was 
rapidly dissected and frozen in liquid nitrogen. Neurochemistry was performed at the 
Vanderbilt Neurochemistry Core Laboratory to assay for biogenic amine 
neurotransmitters, biogenic amine metabolites, amino acids and amino acid 
neurotransmitters. Detection was achieved using Waters high performance liquid 
chromatography (HPLC) systems equipped with autosamplers and either a Decade II 
electrochemical (monoamines) or 474 scanning fluorescence (amino acids) detector. 
 
Statistical Analysis 
 Seizure frequencies for phenotyping studies were compared between double 
mutant and single mutant control littermates using either analysis of variance (ANOVA) 
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with Fisher’s protected least significant difference (PLSD) post hoc tests or unpaired two-
tailed Student’s t-test. Outlier analysis was performed and subjects with seizure 
frequencies two standard deviations above and below the mean at three or six weeks of 
age were removed. Mice with missing three or six week data due to outlier frequencies or 
death were not included in the study. Seizure frequencies for the pyridoxine diet studies 
were compared between modified and control diet mice by unpaired two-tailed Student’s 
t-test. Survival was assessed using Kaplan-Meier analysis with Logrank Mantel-Cox p-
values. Male and female data were analyzed separately, unless otherwise indicated.  
 
Results 
 
Cacna1g 
 
Generation and Evaluation of Cacna1g BAC Transgenic Mice 
 To evaluate the contribution of Cacna1g to the seizure phenotype of F1.Q54 
mice, we generated a Cacna1g BAC transgenic mouse model. Pronuclear injections of 
the BAC clone RP23-65I14, which contained Cacna1g, into SJL fertilized oocytes 
resulted in a single female Cacna1g BAC transgenic founder, designated 1G5. 
Integrity of the 1G5 BAC construct was initially determined using primers 
designed for the SP6 and T7 ends flanking the BAC insert (Table 3.1). The 1G5 founder 
genotyped positive for both end markers. Since the BAC construct was derived from B6 
and injected into SJL, additional genotyping was performed using microsatellite markers 
spanning the BAC to ensure a whole construct was present. The microsatellite markers 
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were located approximately every 32 Kb, including two within Cacna1g (Figure 3.2). All 
markers were found to be heterozygous, suggesting integration of an intact construct. 
 
 
Figure 3.2 Verification of BAC Integrity 
Genotyping was performed to confirm complete integration of the RP23-65I14 BAC into the SJL genome. 
Location of the flanking SP6 and T7 markers and the internal microsatellite markers are indicated. 
 
After confirming the incorporation of an intact BAC construct in the 1G5 line, we 
assessed copy number by qPCR (29). Custom-designed Cacna1g and reference Scn5a 
Taqman assays were previously developed to detect the RP23-65I14 construct (18). We 
plotted ∆Ct values from the copy number standards on the Y-axis with the known copy 
number plotted on the X-axis, using a linear scale. From this, we generated a linear 
trendline with an accompanying y=mx+b slope equation (Figure 3.3). The resulting 
equation was used to estimate copy number of 1G5 hemizygous (n=17), homozygous 
(n=6) and control (n=8) mice. By fitting ∆Ct values (y) from 1G5 offspring DNA, we 
estimated the BAC copy number (x) to be between 5-8 transgene copy integrations. 
During breeding of the 1G5 N2 generation (1G5 Tg N1 male by SJL female), it 
became apparent that the construct integrated onto the X chromosome due to the X-
linked inheritance pattern. Therefore, we intercrossed 1G5 females (N2) and 1G5 males 
(N1) to generate transgene positive males. Offspring from this intercross were obtained in 
the expected Mendelian ratios for an X-linked trait. Females had a 1:1 homozygous 
SP6
D11VU2
D11VU14
D11VU15
D11VU3
D11VU11
D11VU5
D11VU8
T7
3300001P08Rik Ankrd40 Abcc3 Cacna1g Spata20
Epn3
Mycbpap
94,150,000 94,200,000 94,250,000
100 kb mm8
94,300,000
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(n=19) to hemizygous (n=22) ratio and males had a 1:1 hemizygous (n=22) to wildtype 
(n=22) ratio. 
 
 
Figure 3.3 Evaluation of 1G5 Copy Number 
To assess copy number, a Taqman assay was performed on genomic DNA from 1G5 offspring and 
controls. A standard curve was generated with 0, 5, 10 and 20 copies which revealed transgenic mice have 
an estimated 5-8 transgene copy integrations.  
 
As a final evaluation of the 1G5 line, we performed transcript analysis to detect if 
Cacna1g was expressed at an increased level compared to wildtype SJL. RNA was 
extracted from whole brains of six week old hemizygous (Female n=8; Male n=7), 
homozygous (Female n=7) and control (Female n=8; Male n=2) littermates and then 
reverse transcribed. Expression was determined using Taqman gene expression assays for 
Cacna1g (Mm 00486571_m1) and the control Tbp (Mm 00446971_m1). This qPCR 
assay revealed only hemizygous 1G5 males had a significant increase in expression 
compared to wildtype (p < 0.007) (Figure 3.4). Hemizygous 1G5 females were not 
significantly different from wildtype levels. There was a significant two-fold increase in 
expression between homozygous 1G5 females and hemizygous 1G5 females and males 
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(Figure 3.4). These results suggest the 1G5 transgene may be subject to partial X-
inactivation. Complete inactivation of the 1G5 transgene would result in equivalent 
Cacna1g expression levels in homozygous 1G5 females and hemizygous 1G5 males. 
 
 
Figure 3.4 1G5 Expression Using a Taqman qPCR Assay 
To assess expression, a Taqman assay was performed on 1G5 offspring and controls. Fold difference in six 
week old whole-brain expression of Cacna1g are as follows: wildtype controls= 0 ± 0.079, 1G5 
hemizygous females= 0.649 ± 0.037, 1G5 hemizygous males= 1 ± 0.065 and 1G5 homozygous females= 
2.26± 0.032. ANOVA F(3,49)= 15.697, p < 0.0001. P-values were determined by Fishers PLSD post hoc test. 
Error bars represent SEM.   
 
Effect of Cacna1g on F1.Q54 Phenotype 
We systematically evaluated Cacna1g by testing its ability to enhance or reduce 
severity of the F1.Q54 seizure phenotype. To do this, we generated double mutant mice 
by crossing female SJL.1G5 with B6.Q54 males to generate F1 offspring carrying both 
transgenes (F1.1G5;Q54) and controls carrying either F1.Q54 or F1.1G5. Experimental 
mice underwent 30 minute video-taped observations for visible, spontaneous seizures at 
three and six weeks of age. The two time points were then combined to determine the 
seizure frequency in 60 minutes. Seizure analysis of F1.1G5 offspring (Male n=17; 
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Female n=18) revealed no apparent motor seizures. This was consistent with previous 
work on transgenic mice generated with the same BAC construct that exhibited frequent 
behavioral arrest but lacked evident motor seizures or other obvious neurological 
abnormalities (18). Therefore, the average seizure frequency was compared between 
double mutant F1.1G5;Q54 mice and single F1.Q54 controls.  
Double transgenic F1.1G5;Q54 males had significantly more seizures than 
F1.Q54 controls (p < 0.004) (Figure 3.5). No difference in seizure frequency was 
identified between female F1.1G5;Q54 and F1.Q54 controls (p > 0.858) (Figure 3.6). 
Following seizure phenotyping, mice from the SJL.1G5 by B6.Q54 cross were 
retained until 12 weeks of age to examine the effect of Cacna1g overexpression on the 
lifespan of F1.Q54 mice. The transgene had no effect on survival between F1.1G5;Q54 
mice compared to F1.Q54 controls in males or females (Data not shown). 
To properly evaluate the contribution of Cacna1g on the seizure phenotype of 
F1.Q54 mice, at least two separate transgenic lines are required to confirm the phenotype 
and avoid misinterpretation of results due to BAC insertion site effects. At this time, we 
were only able to generate and evaluate one Cacna1g BAC transgenic mouse model, 
designated 1G5. Results from the SJL.1G5 by B6.Q54 cross suggest Cacna1g is a genetic 
modifier of the F1.Q54 phenotype in males. We were unable to reliably determine if 
Cacna1g was a genetic modifier of the F1.Q54 phenotype in females due to the 
possibility that the transgene is subject to X-inactivation. 
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Figure 3.5 Average Seizure Frequency of SJL.1G5 X B6.Q54 Males 
Average number of seizures in 60 minutes for each genotype is shown. Average seizure frequencies for 
males are as follows: F1.1G5= 0, F1.Q54= 22.3 ± 1.76 and F1.1G5;Q54= 29.6 ± 1.68. P-value was 
determined by Student’s t-test. Error bars represent SEM. 
 
 
 
 
Figure 3.6 Average Seizure Frequency of SJL.1G5 X B6.Q54 Females 
Average number of seizures in 60 minutes for each genotype is shown. Average seizure frequencies for 
females are as follows: F1.1G5= 0, F1.Q54= 30.3 ± 2.31 and F1.1G5;Q54= 32.3 ± 2.84. P-value was 
determined by Student’s t-test. Error bars represent SEM. 
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Hlf 
 
Generation of Hlf Double Mutant Mice 
In order to systematically evaluate Hlf, we tested its ability to alter the seizure phenotype 
of F1.Q54 and B6.Q54 mice. To do this, we generated double mutant mice on two strain 
backgrounds. B6.Hlf 
KO/+
 females were first crossed with B6.Q54 males to generate 
B6.Hlf 
KO/+
;Q54 offspring. To generate double mutant animals on the F1 strain 
background, B6.Hlf 
KO/+
;Q54 males were crossed with SJL females. This cross resulted in 
F1.Hlf 
KO/+
;Q54 test mice and controls carrying either F1.Q54 or F1.Hlf 
KO/+
 (Figure 3.7). 
The resulting offspring were obtained at the expected Mendelian ratios. To generate 
double mutant mice on the B6 strain, we crossed B6.Hlf 
KO/+
;Q54 males with B6.Hlf 
KO/+
 
females which resulted in homozygous knockout B6.Hlf 
KO/KO
;Q54 and heterozygous 
knockout B6.Hlf 
KO/+
;Q54 test mice and control littermates carrying B6.Hlf 
KO/+
,     
B6.Hlf 
KO/KO
, or B6.Q54 (Figure 3.7). Offspring from this cross were not obtained at the 
expected Mendelian ratios. While no difference was identified in males, female genotype 
ratios were significantly different (χ2= 17.836, p < 0.003) (Table 3.2). More specifically, 
there was a reduction in female B6.Hlf 
KO/KO
;Q54 and B6.Hlf 
KO/+
 births and an increase 
in B6.Hlf 
KO/+
;Q54 births.  
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Figure 3.7 Generation of Hlf  X B6.Q54 Double Mutant Mice 
Two background strains of Hlf double mutant mice were generated. To produce animals for phenotyping 
experiments, B6.Hlf 
KO/+
;Q54 males were crossed with either B6.Hlf 
KO/+
 or SJL females. Crossing     
B6.Hlf 
KO/+
;Q54 with B6.Hlf 
KO/+
 resulted in homozygous B6.Hlf 
KO/KO
;Q54 and heterozygous             
B6.Hlf 
KO/+
;Q54 test mice and control littermates. Crossing B6.Hlf 
KO/+
;Q54 with SJL resulted in         
F1.Hlf 
KO/+
;Q54 test mice and control offspring. 
 
 
 
 
Table 3.2 Ratio of Genotypes Observed From B6.Hlf 
KO/+
;Q54 X B6.Hlf 
KO/+
 
B6.Hlf 
KO/+
;Q54 males were crossed with B6.Hlf 
KO/+
 females to generate homozygous B6.Hlf 
KO/KO
;Q54 
and heterozygous B6.Hlf 
KO/+
;Q54 mice and control littermates. Males were born at the expected Mendelian 
ratios, while females differed significantly from the expected genotype ratios, predominantly homozygous 
knockout B6.Hlf 
KO/KO
;Q54, heterozygous knockout B6.Hlf 
KO/+
;Q54 and B6.Hlf 
KO/+
. 
 
B6.Hlf KO/+
B6.Hlf KO/+;Q54
B6.Q54
B6.Hlf KO/+ B6.Hlf KO/+;Q54
B6.Hlf KO/KO B6.Hlf KO/KO;Q54
F1.Hlf KO/+
SJL B6.Hlf KO/+;Q54
F1.Q54 F1.Hlf KO/+;Q54
Genotype # Observed # Expected Chi Sq
Males 
(n=392)
B6 56 49
χ2= 2.571 
p > 0.766
B6.Q54 48 49
B6.Hlf  KO/+ 94 98
B6.Hlf  KO/+;Q54 104 98
B6.Hlf  KO/KO 42 49
B6.Hlf KO/KO;Q54 48 49
Females 
(n=414)
B6 55 52
χ2= 17.836  
p < 0.003
B6.Q54 48 52
B6.Hlf  KO/+ 86 104
B6.Hlf  KO/+;Q54 129 104
B6.Hlf  KO/KO 62 52
B6.Hlf KO/KO;Q54 34 52
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Effect of Hlf on F1.Q54 Phenotype 
Offspring from the B6.Hlf 
KO/+
 by SJL cross underwent 30 minute video-taped 
observations for visible, spontaneous seizures at three and six weeks of age. The two time 
points were then combined to determine the seizure frequency in 60 minutes. Seizure 
analysis of F1.Hlf 
KO/+
 offspring (Male n=15; Female n=15) revealed no apparent motor 
seizures. This was consistent with previous work on Hlf knockout mice, not in 
combination with other PAR bZIP knockout lines, which reported no evidence of 
seizures or neurological abnormalities (19). Therefore, average seizure frequency was 
compared by Student’s t-test between double mutant F1.Hlf KO/+;Q54 and F1.Q54 
controls.  
No significant difference in seizure frequency was observed between            
F1.Hlf 
KO/+
;Q54 and F1.Q54 controls in either males (p > 0.348) or females (p > 0.124) 
(Figures 3.8 and 3.9). Although it was not significant, there was a trend towards increased 
seizure frequency in F1.Hlf 
KO/+
;Q54 females compared to F1.Q54 controls. 
Following seizure phenotyping, mice from the F1 cross were retained until 12 
weeks of age to determine if heterozygous loss of Hlf altered the lifespan of F1.Q54 
mice. We did not observe any significant effect on the survival of F1.Hlf 
KO/+
;Q54 mice 
compared to F1.Q54 controls (Data not shown). 
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Figure 3.8 Average Seizure Frequency of B6.Hlf 
KO/+
;Q54 X SJL Males 
Average number of seizures in 60 minutes for each genotype is shown. Average seizure frequencies for 
males are as follows: F1.Hlf 
KO/+
= 0, F1.Q54= 24.8 ± 3.36 and F1.Hlf 
KO/+
;Q54= 20.5 ± 3.03. P-value was 
determined by Student’s t-test. Error bars represent SEM. 
 
 
 
 
 
 
Figure 3.9 Average Seizure Frequency of B6.Hlf 
KO/+
;Q54 X SJL Females 
Average number of seizures in 60 minutes for each genotype is shown. Average seizure frequencies for 
females are as follows: F1.Hlf 
KO/+
= 0, F1.Q54= 17.9 ± 2.63 and F1.Hlf 
KO/+
;Q54= 24.8 ± 3.34. P-value was 
determined by Student’s t-test. Error bars represent SEM. 
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Effect of Hlf on B6.Q54 Phenotype 
Offspring from the B6.Hlf 
KO/+
;Q54 by B6.Hlf 
KO/+
 cross underwent 30 minute 
video-taped observations as described. Seizure analysis of B6.Hlf 
KO/+
 (Male n=15; 
Female n=15) and B6.Hlf 
KO/KO
 (Male n=15; Female n=15) offspring revealed no motor 
seizures, therefore average seizure frequency was compared between heterozygous 
knockout B6.Hlf 
KO/+
;Q54, homozygous knockout B6.Hlf 
KO/KO
;Q54 mice and B6.Q54 
controls by ANOVA.  
A significant difference in seizure frequency was observed in males (F(2,38)= 
6.348, p < 0.004). Double mutant heterozygous B6.Hlf 
KO/+
;Q54 and homozygous   
B6.Hlf 
KO/KO
;Q54 males had significantly (p < 0.001 and p < 0.023, respectively) lower 
seizure frequencies than B6.Q54 controls (Figure 3.10). However, there was no 
significant difference in seizure frequency between heterozygous knockout              
B6.Hlf 
KO/+
;Q54 and homozygous knockout B6.Hlf 
KO/KO
;Q54 male mice (p > 0.353). 
Although we originally hypothesized that loss of Hlf would increase seizure frequency, a 
suggested cause for the reduced seizure frequency emerged from detailed analysis of the 
video records. Male homozygous B6.Hlf 
KO/KO
;Q54 mice experienced a significant 
number of GTCS (χ2= 6.209, p < 0.045) (Figure 3.11). This more severe phenotype is not 
observed in Q54 mice in this age range (5, 7, 8, 32). No significant difference in seizure 
frequency was observed in females (F(2,36) = 0.744, p > 0.482) (Figure 3.12). 
Following seizure phenotyping, we retained mice until 12 weeks of age to 
determine if loss of Hlf altered the lifespan of B6.Q54 mice. We did not observe any 
effect on the survival of heterozygous B6.Hlf 
KO/+
;Q54 or homozygous B6.Hlf 
KO/KO
;Q54 
mice compared to B6.Q54 controls in either males or females (Data not shown). 
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Figure 3.10 Average Seizure Frequency of B6.Hlf 
KO/+
;Q54 X B6.Hlf 
KO/+
 Males 
Average number of seizures in 60 minutes for each genotype is shown. Average seizure frequencies for 
males are as follows: B6.Hlf 
KO/+
= 0, B6.Hlf 
KO/KO
= 0, B6.Q54= 11.6 ± 2.8, B6.Hlf 
KO/+
;Q54= 2.21 ± 0.89 
and B6.Hlf 
KO/KO
;Q54= 4.92 ± 1.52. Significant differences between groups were determined by ANOVA: 
F(2,38) = 6.348, p < 0.004. P-values determined by Fishers PLSD post hoc test. Error bars represent SEM. 
 
 
 
Figure 3.11 Percentage of B6.Hlf 
KO/+
;Q54 X B6.Hlf 
KO/+
 Males Experiencing GTCS 
Percentage of mice experiencing GTCS in 60 minutes for each genotype is shown. Percentages for males 
are as follows: B6.Hlf 
KO/+
= 0%, B6.Hlf 
KO/KO
= 0%, B6.Q54= 0%, B6.Hlf 
KO/+
;Q54= 0% and               
B6.Hlf 
KO/KO
;Q54= 18.9%. P-value was determined by Chi-squared analysis (χ2= 6.209, p < 0.045). 
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Figure 3.12 Average Seizure Frequency of B6.Hlf 
KO/+
;Q54 X B6.Hlf 
KO/+
 Females 
Average number of seizures in 60 minutes for each genotype is shown. Average seizure frequencies for 
females are as follows: B6.Hlf 
KO/+
= 0, B6.Hlf 
KO/KO
= 0, B6.Q54= 13.7 ± 2.87, B6.Hlf 
KO/+
;Q54= 10.2 ± 
3.25 and B6.Hlf 
KO/KO
;Q54= 8.9 ± 1.29. Significant differences between groups were determined by 
ANOVA: F(2,36) = 0.744, p > 0.482. P-values determined by Fishers PLSD post hoc test. Error bars 
represent SEM. 
 
Effect of Pyridoxine Deficient and Enriched Diet on Q54 
To further evaluate our Hlf hypothesis, we tested the effects of pyridoxine 
deficient and enriched diets on the Q54 phenotype. Deletion of the PAR bZIP 
transcription factor family (Hlf, Dbp and Tef ) in a knock-out mouse model resulted in 
mice with spontaneous, generalized tonic-clonic and absence seizures (19). Microarray 
expression analysis was utilized to determine contributors to the epilepsy phenotype (19). 
A two-fold reduction in PDXK, a key enzyme involved in the conversion of pyridoxine 
to PLP, was discovered (19). PLP is a key coenzyme involved in amino acid and 
neurotransmitter metabolism, including GABA (Figure 3.13). We hypothesized that 
B6.Q54 and F1.Q54 mice on pyridoxine deficient diet would have increased seizure 
frequency compared to controls, due to reduced PLP levels. 
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Figure 3.13 Simplified Pyridoxine Pathway 
Loss of the PAR bZIP transcription factor family (Hlf, Dbp and Tef) result in mice with spontaneous GTCS 
and a two-fold reduction in PDXK levels. We predict loss of Hlf alters the pyridoxine pathway, 
consequently reducing GABA and neurotransmitter levels.   
 
   
Furthermore, we evaluated the effect of a pyridoxine enriched diet, to determine if 
elevated levels of pyridoxine reduced seizure frequency in B6.Q54 and F1.Q54 mice.    
Male and female B6.Q54 and F1.Q54 mice were placed on either the modified or control 
diet at three weeks of age and were maintained on the diet for six weeks. At nine weeks 
of age, all mice underwent 30 minute video-taped observations as described above, to 
assess seizure frequency. We also monitored survival until nine weeks of age to 
determine if pyridoxine deficient or enriched diets had any effect on the lifespan. 
Although we provided modified and control diets to B6, F1, B6.Hlf 
KO/+
 and B6.Hlf 
KO/KO
 
male and female mice, no diet effects were detected in any of these groups. Therefore 
data for these groups are not shown. 
No significant difference in seizure frequency was observed in B6.Q54 males 
maintained on the modified diets compared to control diet (p > 0.175, p > 0.598) (Figure 
3.14). While not statistically significant, there was a trend toward increased seizure 
frequency in F1.Q54 males maintained on the deficient and enriched diets compared to 
control diet (p > 0.055 and p > 0.065, respectively).  
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No significant effect was observed when comparing the survival of B6.Q54 males 
maintained on either modified diet compared to controls (Data not shown). However, 
F1.Q54 males maintained on the enriched diet had a significant reduction in lifespan 
compared to controls (p < 0.017) (Figure 3.15). The seizure and survival data indicate 
that the F1.Q54 male phenotype is altered by both pyridoxine deficient and enriched 
diets, while the B6.Q54 male phenotype is not changed by either modified diet. 
A significant difference in seizure frequency was observed in females. B6.Q54 
females maintained on a pyridoxine deficient diet had significantly more (p < 0.017) 
seizures compared to B6.Q54 females on the control diet (Figure 3.16). No change was 
observed in B6.Q54 females on the pyridoxine enriched diet (p > 0.893). No significant 
difference in seizure frequency was observed in F1.Q54 females maintained on either 
modified diet (p > 0.451 and p > 0.564, respectively) (Figure 3.16).  
A significant reduction in the lifespan of B6.Q54 females maintained on the 
pyridoxine deficient diet compared to controls was identified (p < 0.011) (Figure 3.17). 
No significant effect was observed when comparing the survival of F1.Q54 females 
maintained on either modified to controls (Data not shown). The seizure and survival data 
indicate that the B6.Q54 female phenotype is altered by a pyridoxine deficient diet, while 
the F1.Q54 female phenotype is not changed by either modified pyridoxine diet. 
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Figure 3.14 Average Seizure Frequency of Males on Modified Pyridoxine Diets 
Average number of seizures in 30 minutes for each genotype is shown. Average seizure frequencies for 
males are as follows: Control B6.Q54= 0.188 ± 0.101, Deficient B6.Q54= 0.6 ± 0.34, Enriched B6.Q54= 
0.3 ± 0.213, Control F1.Q54= 0.587 ± 0.345, Deficient F1.Q54= 2.46 ± 0.779 and Enriched F1.Q54= 3.2 ± 
1.828. Significant differences were determined by Student’s t-test. Error bars represent SEM. 
 
 
 
 
 
 
 
 
 
Figure 3.15 Kaplan Meier Survival of F1.Q54 Males on Modified Pyridoxine Diets 
Survival of F1.Q54 male mice maintained on control, deficient or enriched pyridoxine diets are shown. 
Survival was monitored until 9 weeks of age. P-value was determined by Logrank Mantel-Cox. 
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Figure 3.16 Average Seizure Frequency of Females on Modified Pyridoxine Diets 
Average number of seizures in 30 minutes for each genotype is shown. Average seizure frequencies for 
females are as follows: Control B6.Q54= 0.117 ± 0.081, Deficient B6.Q54= 0.91 ± 0.368, Enriched 
B6.Q54= 0.1 ± 0.1, Control F1.Q54= 4.23 ± 1.29, Deficient F1.Q54= 3 ± 0.699 and Enriched F1.Q54= 
3.11 ± 1.328. Significant differences were determined by Student’s t-test. Error bars represent SEM. 
 
 
 
 
 
 
 
 
Figure 3.17 Kaplan Meier Survival of B6.Q54 Females on Modified Pyridoxine Diets 
Survival of B6.Q54 female mice maintained on control, deficient or enriched pyridoxine diets are shown. 
Survival was monitored until 9 weeks of age. P-value was determined by Logrank Mantel-Cox. 
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Effect of Pyridoxine Deficient Diet on Neurochemistry  
 A subset of mice maintained on the pyridoxine deficient and control diets were 
used for neurochemistry studies. Neurochemistry assays for biogenic amine 
neurotransmitters and metabolites, amino acids and amino acid neurotransmitters were 
used to determine if the deficient diet altered brain chemistry. 
Relevant to our phenotyping studies, F1.Q54 males on the deficient diet had a 
significant increase in glutamate and GABA concentration compared to controls (Figure 
3.18). This supports our seizure data which indicated F1.Q54 males on the deficient diet 
had more seizures compared to controls (Figure 3.14). Although B6.Q54 females 
experienced increased seizures on the deficient diet, no significant difference in 
glutamate or GABA was identified (Data not shown).  
Regardless of genotype, all males maintained on the pyridoxine deficient diet had 
detectable brain concentrations of proline, while controls did not (Figure 3.19). B6 and 
B6.Q54 males on the deficient diet had significant differences in proline concentration 
compared to controls (p < 0.027 and p < 0.024, respectively). Proline was not detected in 
any females. Altered proline concentrations, such as those in Hyperprolinemia type II, 
cause pyridoxine deficiency by endogenous accumulation of the PLP deactivator P5C, 
resulting in pyridoxine dependent seizures (21, 33). This suggests that males, in particular 
B6 and B6.Q54, are more susceptible to the metabolic changes associated with a 
pyridoxine deficient diet, although an obvious phenotype was not observed. 
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Figure 3.18 F1.Q54 Male Brain Concentrations of Glutamate and GABA 
F1.Q54 male mice were maintained on the deficient or control diet for six weeks. Glutamate and GABA 
concentrations were assayed in forebrain. Average concentrations are as follows: Glutamate: F1.Q54 
control= 139.6  ± 7.34 and F1.Q54 deficient= 194.4 ± 10.7. GABA: F1.Q54 control= 34.4 ± 3.11 and 
F1.Q54 deficient= 44.5 ± 2.71. P-values determined by Student’s t-test. Error bars represent SEM. 
 
 
 
 
 
Figure 3.19 Proline Concentrations Identified in Males 
Male mice were maintained on the deficient or control diet for six weeks. Proline concentrations were 
assayed in forebrain. Average concentrations are as follows: B6, B6.Q54, B6.Hlf 
KO/+
, B6.Hlf 
KO/KO
, F1 and 
F1.Q54 controls= 0, B6 deficient= 8.74 ± 3.02, B6.Q54 deficient= 8.89 ± 2.97, B6.Hlf 
KO/+
 deficient= 2.63 
± 2.63, B6.Hlf 
KO/KO
 deficient= 2.42 ± 2.42, F1 deficient= 5.96 ± 3.45 and F1.Q54 deficient= 4.07 ± 4.07. 
P-values determined by Student’s t-test. * represents significance compared to control diet. * < 0.01. Error 
bars represent SEM.  
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Effect of Hlf on the Dravet Phenotype of Scn1a
KO/+
 Heterozygous Knockout Mice 
To determine whether Hlf would modify other types of epilepsy, we assessed the 
ability of Hlf to alter the Dravet phenotype of Scn1a
KO/+
 heterozygous knockout mice. To 
do this, we generated double mutant mice by crossing B6.Hlf 
KO/+
 females with 
129.Scn1a
KO/+
 males to generate F1 double heterozygous knockout F1.Hlf 
KO/+
;Scn1a
KO/+
 
offspring and controls carrying either F1.Hlf 
KO/+
 or F1.Scn1a
KO/+
. Double heterozygous 
and control mice were then monitored for survival until 12 weeks of age to determine if 
loss of Hlf altered the lifespan of F1.Scn1a
KO/+
 mice. A significant reduction in lifespan 
was observed between F1.Hlf 
KO/+
;Scn1a
KO/+
 and control F1.Scn1a
KO/+
 mice (p < 0.001) 
(Figure 3.20). By four weeks of age, only 45% of double heterozygous knockout     
F1.Hlf 
KO/+
;Scn1a
KO/+
 mice survived, compared to the 71% survival rate of F1.Scn1a
KO/+
 
mice. By 12 weeks of age, only 29% of F1.Hlf 
KO/+
;Scn1a
KO/+
 mice survived compared to 
42% of F1.Scn1a
KO/+
 mice. As expected, F1.Hlf 
KO/+
 mice have no phenotype with 100% 
survival throughout the study. 
 
Figure 3.20 Kaplan Meier Survival of B6.Hlf 
KO/+
 X 129.Scn1a
KO/+
 Mice 
Survival of F1.Hlf 
KO/+
, F1.Scn1a
KO/+
 and F1.Hlf 
KO/+
;Scn1a
KO/+
 mice are shown. Survival was monitored 
until 12 weeks of age. Kaplan Meier analysis was performed. P-value determined by Logrank Mantel-Cox. 
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Discussion 
We previously mapped a dominant locus on chromosome 11, designated Moe1, 
which modified seizure susceptibility of Q54 mice. Fine-mapping and RNA-Seq data 
suggested two sex-specific candidate modifier genes at the Moe1 locus: Cacna1g in 
females and Hlf in males (8). To determine the contribution of these genes to the seizure 
phenotype of Q54 mice, we utilized Cacna1g BAC transgenic and Hlf targeted knockout 
mouse models. We systematically evaluated the candidate modifier genes by testing their 
ability to enhance or reduce seizure severity of the Q54 phenotype in double mutant 
mice. In addition to seizure analysis, we also evaluated our Hlf hypothesis by testing the 
effects of modified dietary pyridoxine on the Q54 phenotype and assessed Hlf’s ability to 
modify the Dravet phenotype of Scn1a
KO/+
 mice.  
 
Validation of Cacna1g as a Genetic Modifier of F1.Q54 Mice 
Cacna1g, encoding the T-type calcium channel α1 subunit, was prioritized as a 
top candidate modifier gene of the Moe1 locus based on previous research attributing 
Cacna1g mutations to human and mouse epilepsy (8, 10, 11). Cacna1g was hypothesized 
to modify the Q54 seizure phenotype through significant strain-specific differences in 
expression profiles of transcripts which have functional diversity (8). Cacna1g channels 
preferentially expressed in SJL females reduce synchronous thalamocortical oscillations, 
a common feature of epilepsy, while B6 females express Cacna1g channels prone to 
hyperexcitability (8, 16-18). Therefore, we wanted to systematically evaluate 
overexpression of B6 Cacna1g to determine if it increased the seizure frequency of 
F1.Q54 mice. 
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To evaluate the contribution of Cacna1g to the seizure phenotype of F1.Q54 
mice, we generated a Cacna1g BAC transgenic mouse model. It was determined that the 
1G5 line had X-chromosome integration of an estimated 5-8 transgene copies and 
expressed Cacna1g at increased levels compared to wildtype. Double transgenic 
F1.1G5;Q54 males had significantly more seizures than F1.Q54 controls, while there was 
no difference in females.  
Although previous mapping data (Chapter II) suggested Cacna1g as a female-
specific modifier, results from female F1.1G5;Q54 mice were difficult to interpret due to 
the possibility that the transgene may be subject to X-inactivation (8). Prior work 
indicated transgene integration onto the X chromosome can result in partial or complete 
inactivation (8, 34-36). Total or partial inactivation of the 1G5 BAC may have resulted in 
incomplete transgene expression. Consequently, seizure frequency of F1.1G5:Q54 
females may not be altered due to technical reasons. Moreover, it is possible that females, 
which already have a high seizure frequency, may experience a ceiling effect.  
While our previous mapping data did not suggest Cacna1g as a candidate 
modifier in males, it is not unexpected as CACNA1G is directly involved in human 
epilepsy (8, 11). We hypothesize that males may have a protective modifier gene in Moe1 
which may have masked Cacna1g’s effect on seizure frequency in our mapping study (8). 
Future work is necessary to verify the full modifier potential of Cacna1g, including 
generation of additional Cacna1g BAC transgenic lines. 
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Validation of Hlf as a Genetic Modifier of Q54 Mice 
Hlf, encoding hepatic leukemia factor, a PAR bZIP transcription factor, was 
prioritized as a top candidate modifier gene of the Moe1 locus in males. This was based 
on a PAR bZIP transcription factor family knockout mouse model that experienced 
spontaneous GTCS and absence seizures (19). Further analysis of the model revealed a 
reduction in PDXK, a key enzyme involved in the conversion of pyridoxine to PLP (19). 
PLP is a key coenzyme involved in amino acid and neurotransmitter metabolism, 
including GABA and glutamate (20). PLP has a substantial connection to human and 
mouse epilepsy, as pyridoxine-dependent epilepsies are successfully treated with PLP 
and mice defective in PLP metabolism experience fatal seizures (21, 25).  
Hlf was hypothesized to modify the Q54 seizure phenotype by contributing to 
strain-specific PDXK and PLP levels (Figure 3.1) (8). Hlf is expressed at a significantly 
reduced level in B6 males compared to SJL (8). Furthermore, we observed a trend toward 
significant reduction of PDXK expression (p > 0.135) in B6 males compared to SJL in 
brain RNA-Seq analysis (Unpublished observations, N. Hawkins and J. Kearney,). These 
reductions in B6 may decrease PLP levels, consequently increasing seizure susceptibility. 
Therefore we wanted to systematically evaluate if loss of Hlf would increase seizure 
frequency of F1.Q54 and B6.Q54 mice. 
On the F1 strain, no significant differences in seizure frequency or survival were 
observed between heterozygous knockout F1.Hlf 
KO/+
;Q54 mice and F1.Q54 controls in 
either sex. This outcome was expected as SJL mice express Hlf at significantly increased 
levels compared to B6. The single SJL Hlf copy may be enough to support sufficient 
PDXK and PLP levels. 
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On the B6 strain, double mutant heterozygous knockout B6.Hlf 
KO/+
;Q54 and 
homozygous knockout B6.Hlf 
KO/KO
;Q54 males had significantly lower seizure 
frequencies compared to B6.Q54 controls. We originally hypothesized that loss of Hlf 
would increase seizure frequency. While B6.Hlf 
KO/+
;Q54 and B6.Hlf 
KO/KO
;Q54 had 
reduced total focal motor seizures compared to controls, B6.Hlf 
KO/KO
;Q54 males 
experienced GTCS not traditionally seen in the B6.Q54 model. Although much older 
B6.Q54 mice may experience rare GTCS, in our previous studies of B6.Q54 we never 
observed GTCS at three or six weeks of age (5, 7, 8, 32). Therefore, we conclude that 
complete loss of Hlf exacerbated the seizure phenotype of B6.Q54 male mice. 
No significant difference in seizure frequency was observed in B6.Hlf 
KO/+
;Q54 or 
B6.Hlf 
KO/KO
;Q54 females. Although an overt seizure phenotype was not detected in 
either heterozygous or homozygous knockout females, B6.Hlf 
KO/+
, heterozygous    
B6.Hlf 
KO/+
;Q54 and homozygous B6.Hlf 
KO/KO
;Q54 females were born at significantly 
altered ratios than expected. The ratio shift suggests reduced viability of                  
B6.Hlf 
KO/KO
;Q54 females. Future studies will determine if B6.Hlf 
KO/KO
;Q54 females are 
dying before tail biopsy at P14 or are not being born. Either outcome suggests Hlf 
modifies the survival of female B6.Q54 mice. 
In addition to seizure analysis, we evaluated our Hlf hypothesis by testing the 
effects of pyridoxine deficient and enriched diets on the Q54 phenotype. We 
hypothesized that a pyridoxine deficient diet would increase seizure frequency, based on 
past data which revealed mice maintained on a deficient diet experienced increased 
seizure frequency (22-24). B6.Q54 females on the pyridoxine deficient diet had increased 
seizure frequency and reduced survival compared to controls. The B6.Q54 male seizure 
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phenotype was not altered. This could be due to a variety of reasons, including the 
relatively short length of time mice were maintained on the deficient diet. 
Neurochemistry studies revealed B6.Q54 males maintained on the deficient diet had 
significant levels of proline detected in their brains, whereas controls had zero. 
Hyperprolinemia has been associated with seizures and epilepsy (21). This may indicate 
the start of an altered metabolic state in male B6.Q54 mice and suggests that a phenotype 
may emerge if the deficient diet was continued for longer than six weeks. Although 
F1.Q54 females maintained on the pyridoxine deficient diet had no changes in seizure 
frequency or survival, F1.Q54 males on the deficient diet had near significant increases in 
seizure frequency. Neurochemistry studies revealed F1.Q54 males had significant 
changes in glutamate and GABA concentrations compared to controls. Given the 
functions of glutamate and GABA, we predict these altered levels may contribute to the 
modified seizure phenotype of F1.Q54 male mice.  
We hypothesized a pyridoxine enriched diet would decrease seizure frequency, 
given pyridoxine dependent epilepsies are successfully treated with PLP (21). No 
reduction in seizure frequency was observed in B6.Q54 males or females maintained on 
the pyridoxine enriched diet. It is possible that the already low seizure frequency of 
B6.Q54 mice may make significant reductions impossible due to floor effects. 
Alternatively, pyridoxine enrichment may not have an effect on seizure frequency in 
B6.Q54 mice. F1.Q54 females maintained on the pyridoxine enriched diet had no 
changes in seizure frequency or survival. F1.Q54 males had increased seizure frequency 
and reduced survival on the enriched diet compared to controls. Of the ten F1.Q54 males 
maintained on the enriched diet, only five survived until 9 weeks of age. At least in 
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males, pyridoxine enrichment has no positive effect on reducing the seizure phenotype of 
F1.Q54 mice, rather it exacerbates the seizure phenotype.  
Finally, Hlf was shown to modify the Dravet phenotype of Scn1a
KO/+
 
heterozygous knockout mice. Double heterozygous knockout F1.Hlf 
KO/+
;Scn1a
KO/+
 mice 
had a significant reduction in lifespan compared to controls. By four weeks of age, only 
45% of F1.Hlf 
KO/+
;Scn1a
KO/+
 mice survived compared to 71% of F1.Scn1a
KO/+
 controls. 
The Scn1a
KO/+
 mice recapitulate many features of Dravet syndrome, including 
development of early onset epilepsy, spontaneous seizures and premature death (37, 38). 
It is hypothesized that reduced sodium currents in GABAergic inhibitory interneurons are 
responsible for the Scn1a
KO/+
 seizure phenotype (38). Our Scn1a
KO/+
 model replicated 
those studies and identified an increase in sodium current density in pyramidal neurons 
(28). The loss of Hlf, hypothesized to reduce PDXK and PLP, may alter neurotransmitter 
synthesis. This in combination with Scn1a
KO/+
 increased hyperexcitability, may be 
responsible for the decreased survival seen in F1.Hlf 
KO/+
;Scn1a
KO/+
 mice.  
Through seizure analysis and modified diet studies, Hlf was shown to be a 
modifier of the Q54 phenotype. Although previous data did not suggest Hlf as a female 
candidate modifier gene, it is not unexpected, as loss of Hlf is hypothesized to alter PLP 
enzyme levels and thus increase seizure susceptibility. Furthermore, Hlf was shown to 
modify the phenotype of Dravet mice. Future identification of HLF risk variants in 
epilepsy patients would validate this gene as a contributor to human epilepsy. 
Verification of Cacna1g and Hlf as epilepsy modifier genes may suggest new 
targets for improved treatment of epilepsy and advance molecular diagnostic capabilities 
by identifying those patients who are most at-risk for developing severe epilepsy. 
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CHAPTER IV 
 
NEURONAL VOLTAGE-GATED ION CHANNELS ARE GENETIC MODIFIERS OF 
GENERALIZED EPILEPSY WITH FEBRILE SEIZURE PLUS* 
 
Introduction 
During the past 20 years, research has revealed several genes underlying rare 
monogenic forms of idiopathic generalized epilepsy (IGE); however there has been less 
progress towards the identification of genes involved in the more common, genetically 
complex forms of IGE (1-3). Many of the genes now known to cause monogenic forms of 
epilepsy encode neuronal ion channel subunits, including voltage-gated sodium and 
potassium channels. Mutations in the voltage-gated sodium channel genes SCN1A, 
SCN2A and SCN1B result in genetic epilepsy with febrile seizures plus (GEFS+) (4-
6).We recently generated a mouse model of GEFS+ by introducing the human 
SCN1A
R1648H
 GEFS+ mutation, which was identified in a large pedigree with 13 affected 
members, into the orthologous mouse Scn1a gene (7). 
Scn1a
R1648H/+
 heterozygous mutants display a normal lifespan, reduced thresholds 
to flurothyl and hyperthermia induced seizures and infrequent spontaneous generalized 
seizures as adults (7). Scn1a
R1648H/R1648H 
homozygous mice exhibit spontaneous 
generalized seizures and have an average lifespan of 18.5 days. Cortical interneurons 
from Scn1a
R1648H/+ 
and Scn1a
R1648H/R1648H
 mice display slowed recovery from 
inactivation,  increased  use-dependence   and a   reduced ability to fire  action  potentials. 
 
  
*Modified from: Hawkins NA, Martin MS, Frankel WN, Kearney JA and Escayg A. (2011) Neuronal 
voltage-gated ion channels are genetic modifiers of generalized epilepsy with febrile seizure plus. 
Neurobiology of Disease, 41, 655-660.   
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These electrophysiological abnormalities are predicted to reduce the level of GABAergic 
inhibition, providing a mechanism for seizure generation (7). 
Mutations in the voltage-gated sodium channel gene SCN2A have also been 
associated with human epilepsy syndromes including GEFS+, benign familial neonatal-
infantile seizures (BFNIS), Dravet and Ohtahara syndromes (8-10). The transgenic mouse 
model Scn2a
Q54
 (Q54) has a gain-of function mutation in Scn2a, resulting in a 
progressive epilepsy phenotype characterized by focal motor seizures that begin in the 
second month of life. Later development of secondary generalized seizures and a reduced 
lifespan also occur. Hippocampal pyramidal neurons from Q54 mice exhibit increased 
persistent sodium current (11). 
Mutations in the voltage-gated potassium channel genes KCNQ2 and KCNQ3 are 
associated with benign familial neonatal convulsions (BFNC). This syndrome is 
characterized by clusters of seizures in the first days of life and remission within the first 
year (12-14). KCNQ2 and KCNQ3 encode Kv7.2 and Kv7.3 respectively, which 
heterodimerize to form a slowly activating and inactivating voltage-gated potassium 
channel. These channels generate M current, important for controlling repetitive firing 
upon strong excitatory stimulation (15, 16). The Kcnq2
V182M/+
 line was generated by 
ethylnitrosourea (ENU) mutagenesis and carries the amino acid substitution in the third 
transmembrane segment of Kcnq2. Heterozygous Kcnq2
V182M/+
 mutants exhibit reduced 
thresholds for minimal clonic seizures and rare spontaneous seizures as adults even 
though they have a normal lifespan (17). We previously showed genetic interaction 
between Scn2a and Kcnq2 in mice (17). 
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SCN8A mutations are associated with ataxia and behavioral abnormalities in 
humans and movement disorders in mice. Mice homozygous for the Scn8a
med-jo
 missense 
mutation exhibit tremor and cerebellar ataxia. Although Scn8a
med-jo
 heterozygous mutants 
have no visible abnormalities, they do have spontaneous spike-wave discharges 
characteristic of non-convulsive absence seizures (18-21). We recently found that the 
loss-of-function mutations in heterozygous Scn8a
med-jo
 mutants and heterozygous 
Scn8a
med/+
 mutants were more resistant to flurothyl and kainic acid induced seizures. We 
also showed that the Scn8a
med-jo
 allele could rescue the reduced seizure threshold and 
premature lethality of heterozygous Scn1a knockout (Scn1a
KO/+
) mice, suggesting that 
Scn8a may play an important role in the excitatory circuits that influence convulsive 
seizure thresholds (22). 
Unrelated individuals with GEFS+ exhibit a wide range of epilepsy subtypes and 
severities that may reflect, in part, the relative effect of different SCN1A mutations on 
channel function. Similar variability is also seen between affected family members who 
carry the same SCN1A mutation (23, 24). This suggests that in addition to the primary 
mutation, the clinical manifestation of epilepsy can be influenced by other factors such as 
stochastic events during development, environmental influences or genetic modifiers. 
Mouse models with sodium channel mutations exhibit variable phenotypes depending on 
the genetic background, supporting a role for genetic modifiers (17, 25-27). Based on 
these observations, we hypothesize that genetic modifier loci may contribute to the 
variable clinical presentation observed in GEFS+. 
To test the hypothesis that genetic modifiers can contribute to GEFS+ variability, 
we examined the effect of mutations in Scn2a, Kcnq2 and Scn8a on the epilepsy 
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phenotype of the Scn1a
R1648H/+
 mouse model. Here we demonstrate that mutations in 
Scn2a and Kcnq2 exacerbate the phenotype, whereas altered Scn8a function ameliorates 
it. Our results provide support for genetic modification as one mechanism by which the 
clinical presentation of GEFS+ can be altered, indicating that neuronal excitability is 
influenced by the net activity of ion channels. 
 
Materials and Methods 
 
Mice 
Kcnq2
V182M/+
 mice were generated by ENU mutagenesis (http://nmf.jax.org) at 
The Jackson Laboratory (Jackson Labs stock #004703). Kcnq2
V182M/+
 heterozygous 
mutants are maintained by continued backcrossing to C57BL/6J (B6) background strain 
(Jackson Labs stock #000664). Q54 transgenic mice congenic on the B6 strain (B6.Q54) 
were established as described and are maintained by continued backcrossing of 
hemizygous B6.Q54 males to B6 females (Jackson Labs stock #000664) (25). Scn8a
med-jo
 
mice were obtained from The Jackson Laboratory and are maintained on the B6 
background (Jackson Labs stock #003798). Scn1a
R1648H/+
 mice were generated as 
previously described (7). Scn1a
R1648H/+
 mice on a mixed 129S6.C57BL/6J(N2–3) 
background were used for mating with Scn8a
med-jo
 mice. Scn1a
R1648H/+
 mice on the 
129S6/SvEvTac (129) background were used for mating with B6.Q54 and 
B6.Kcnq2
V182M/+
 mice. 129.Scn1a
R1648H/+
, B6.Q54, B6.Kcnq2
V182M/+
 and Scn8a
med-jo
 mice 
were genotyped as previously described (7, 11, 17, 22). 
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Generation of Double Mutant Mice 
Double heterozygous mutants were generated by crossing 129.Scn1a
R1648H/+
 
females with B6.Kcnq2
V182M/+
 or B6.Q54 males generating F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 
or F1.Scn1a
R1648H/+
;Q54 mice and F1 control littermates. Scn1a
R1648H/+
 females on a 
mixed B6/129 background were used for mating to Scn8a
med-jo
 males. 
Scn1a
R1648H/R1648H
;Scn8a
med-jo
 mutants and controls were generated by crossing 
Scn1a
R1648H/+
;Scn8a
med-jo
 males with Scn1a
R1648H/+
 females. All double mutants were 
obtained at expected Mendelian ratios. Littermates were used for all experiments to 
minimize variation due to differences in genetic background. Mice were housed in 
pathogen-free mouse facilities with 12-h light/dark cycles. Food and water were available 
ad libitum. All experimental protocols were approved by the Emory University and 
Vanderbilt University IACUC committees. 
 
Flurothyl Seizure Induction  
Mice between eight and twelve weeks of age were placed in a clear Plexiglas 
chamber and flurothyl (2,2,2-trifluroethylether) was slowly introduced into the chamber 
via a syringe pump at a rate of 20 μl/min and allowed to volatilize (Sigma-Aldrich). 
Seizure thresholds were determined by measuring latency to the first myoclonic jerk (MJ) 
and generalized tonic-clonic seizure (GTCS). The MJ is the first observable behavioral 
response, characterized by a brief jerk of the shoulders and/or neck. The GTCS is 
characterized by convulsions of the entire body and loss of posture. Data from males and 
females were analyzed separately. No sex differences were observed therefore data from 
both sexes were combined. Statistical analysis between genotypes was performed using 
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one-way analysis of variance (ANOVA) followed by Fisher's protected least significant 
difference (PLSD) post hoc test. 
 
Video-ECoG Monitoring  
Mice were implanted with prefabricated headmounts for video- 
Electrocorticography (ECoG) monitoring (Pinnacle Technology, Inc.). Briefly, mice were 
anesthetized with isoflurane and placed in a stereotaxic frame and headmounts were 
attached to the skull with four stainless steel screws that serve as cortical surface 
electrodes (Kopf). Headmounts were positioned 0–0.5 mm posterior to lambda. The 
anterior screw electrodes were 0.5–1 mm posterior to bregma and 1 mm lateral from the 
midline. The posterior screws were 4.5–5 mm posterior to bregma. After ≥ 24 hours of 
recovery, mice were placed in a Plexiglas bowl (14" h×16" diameter) and ECoG data 
were collected from freely moving mice. Acquisition and analysis of digitized data was 
performed with Sirenia software along with contemporaneous video recordings (Pinnacle 
Technology, Inc.). Epileptiform activity was scored manually.  
 
Results 
 
Q54 and Kcnq2
V182M/+
 Alleles Exacerbate the Phenotype of Scn1a
R1648H/+
 Mutants 
To model the effect of inheriting mutations in sodium channel genes Scn1a and 
Scn2a, we generated F1.Scn1a
R1648H/+
;Q54 double mutants by crossing 129.Scn1a
R1648H/+
 
females with B6.Q54 males. Sporadic death of F1.Scn1a
R1648H/+
;Q54 double mutants 
began to occur at postnatal day 16 (P16) with 100% mortality by P24 (Figure 4.1). 
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Beginning at postnatal day 16 (P16), F1.Scn1a
R1648H/+
;Q54 double mutants exhibited 
spontaneous focal motor seizures and GTCS. In 137 hours of ECoG recording, we 
observed 25 GTCS and 11 focal motor seizures (Table 4.1; Figure 4.2B). Generalized 
seizures lasted 45–100 s, during which time mice experienced repetitive jerking of all 
four limbs and neck, running, jumping and tail clonus. These seizures often ended with 
tonic hindlimb extension, indicative of a severe seizure. During ECoG recording we 
observed two F1.Scn1a
R1648H/+
;Q54 mice that had severe seizures with hindlimb 
extension followed by death. Focal motor seizures lasted 10 s and were characterized by 
forelimb clonus. F1.Q54 littermates displayed a similar number of focal motor seizures. 
However, GTCS were rare in F1.Q54, with only one observed during 168 hours of ECoG 
recordings (Table 4.1). We saw no seizures in F1.Scn1a
R1648H/+
 littermates (Table 4.1, 
Figure 4.2A). This was expected as previous monitoring of three to five month old 
Scn1a
R1648H/+
 mice detected spontaneous seizures with a low average frequency of one 
seizure per 64 hours of recording (7). 
To model the effect of inheriting mutations in Scn1a and Kcnq2, we generated 
F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 double heterozygous mutants by crossing 
129.Scn1a
R1648H/+ 
females with B6.Kcnq2
V182M/+
 males. At P19, sporadic death of 
F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 mice began to occur, with 42% mortality by P25, 
demonstrating the ability of the Kcnq2
V182M
 allele to exacerbate the phenotype of 
Scn1a
R1648H/+
 mice (Figure 4.1). Interestingly, 47% of F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 
double heterozygous mutants survived for more than 100 days (Figure 4.1). 
At P16, F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 mice began to display spontaneous 
generalized seizures. In 330 hours of ECoG recording, we observed 87 MJ, four GTCS 
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and one focal motor seizure in F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 double heterozygous 
mutants (Table 4.1; Figure 4.2C). During a generalized seizure the mice typically 
experienced repetitive jerking of all four limbs and neck, running, jumping and tail 
clonus. Generalized seizures were periodically followed by tonic extension of the 
hindlimbs. During ECoG recording we observed two F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 mice 
that had severe seizures with hindlimb extension followed by death. Epileptiform events 
were not observed in F1.Scn1a
R1648H/+
 or F1.Kcnq2
V182M/+
 control littermates (Table 4.1).  
 
Table 4.1 Recorded ECoG Events from F1 Double Mutant Mice 
Video ECoG data was collected from freely moving mice. Double mutants and single mutant control 
littermates (n ≥ 3) were observed in 12 hour intervals. Data acquisition and analysis were performed with 
contemporaneous video. Epileptiform activity was manually scored. 
 
 
 
Figure 4.1 Survival of F1 Double Mutant and Control Littermates 
Survival of F1 double mutant mice and littermate controls are shown. Survival was monitored until 100 
days of age. All genotypes had n ≥ 24. 
Genotype
Events
n Age Range (Days)
Total Hours of 
ECoG monitoringGTCS Partial MJ
F1.Scn1aR1648H/+;Q54 25 11 3 5 17-21 137
F1.Scn1aR1648H/+;
Kcnq2V182M/+
4 1 87 7 18-36 330
F1.Scn1aR1648H/+ 0 0 0 4 18-42 240
F1.Q54 1 14 0 3 17-25 168
F1.Kcnq2V182M/+ 0 0 0 3 22-44 350
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Figure 4.2 Q54 and Kcnq2
V182M/+
Alleles Exacerbate the Scn1a
R1648H/+
 Phenotype 
A. Representative normal ECoG pattern from a control F1.Scn1a
R1648H/+
 heterozygote mouse. B. 
Representative ECoG recording from a F1.Scn1a
R1648H/+
;Q54 double heterozygous mutant during a seizure. 
C. Representative ECoG recording from a F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 double heterozygous mutant 
during a seizure. Channel 1 recorded from right posterior to left posterior. Channel 2 recorded from right 
anterior to left posterior. 
 
Scn8a Dysfunction Restores Normal Seizure Thresholds in Scn1a
R1648H/+
 Mutants  
We previously demonstrated that two heterozygous Scn8a mutants, Scn8a
med-jo 
and Scn8a
med
, exhibited increased resistance to flurothyl and kainic acid induced seizures 
(22). In contrast, Scn1a
R1648H/+
 mutants had reduced thresholds to flurothyl induced 
GTCS (7). To investigate whether the Scn8a
med-jo
 allele could alter convulsive seizure 
thresholds in Scn1a
R1648H/+
 mice, we generated double heterozygous 
Scn1a
R1648H/+
;Scn8a
med-jo
   mutants.   Thresholds   to   flurothyl   induced   seizures   were  
C
B
A
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Figure 4.3 Latency to Flurothyl Induced Seizures 
Average latency in minutes to the first GTCS is shown. Group sizes were n=9-10. Significant differences 
between groups were determined by ANOVA: F(3,35)= 9.858, p < 0.001. P-values were determined by 
Fisher’s PLSD post hoc test. * indicated p < 0.05 compared to wildtype littermates. # indicates p < 0.001 
compared with Scn1a
R1648H/+
 mutants. Error bars represent SEM. 
 
compared between Scn1a
R1648H/+
;Scn8a
med-jo 
double mutants and control single 
heterozygote and wildtype littermates, which revealed a significant effect by ANOVA 
(F(3,35)= 9.858, p < 0.001) . In agreement with our previous observations, the average 
latency to flurothyl-induced GTCS in Scn8a
med-jo
 mutants was 30% longer compared to 
wildtype littermates (Figure 4.3) (7, 22). Post hoc analysis of the increased latency to 
GTCS experienced by Scn8a
med-jo
 compared to wildtype littermates was statistically 
significant (p < 0.05). In contrast, a 21% reduction was observed in Scn1a
R1648H/+
 mutants 
when compared to wildtype littermates, which was statistically significant (p < 0.05) by 
post hoc analysis (Figure 4.3). The average latency to GTCS of Scn1a
R1648H/+
;Scn8a
med-jo
 
double mutants was 50% longer compared to Scn1a
R1648H/+
 mutants. Post hoc analysis 
revealed the increased latency to GTCS observed in Scn1a
R1648H/+
;Scn8a
med-jo
 double 
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mutants was statistically significant when compared to Scn1a
R1648H/+
 mutants (p < 0.001), 
but not statistically different from wildtype littermates (p > 0.05). These results 
demonstrate seizure thresholds can be restored to more normal levels in Scn1a
R1648H/+
 
mice by altering the function of Scn8a. 
 
Scn8a
med-jo
 Mutation Prolongs the Lifespan of Scn1a
R1648H/R1648H
 Mutants 
To determine whether the presence of the Scn8a
med-jo
 allele could improve the 
survival of homozygous Scn1a
R1648H/R1648H
 mice, we compared the lifespans of 
Scn1a
R1648H/R1648H
 and Scn1a
R1648H/R1648H
;Scn8a
med-jo
 littermates. Similar to previous 
observations, Scn1a
R1648H/R1648H
 mutants exhibited 50% mortality by P19.5 and 100% 
lethality by P25 (Figure 4.4) (7). In contrast, only 25% mortality was observed for 
Scn1a
R1648H/R1648H
;Scn8a
med-jo
 mice at P25 and 47% of these mutants survived for over 
100 days, a significant (p < 0.001) improvement compared to controls (Figure 4.4).  
 
 
Figure 4.4 Survival of Scn1a
R1648H/R1648H
;Scn8a
med-jo
 and Control Littermates 
Survival of double mutant Scn1a
R1648H/R1648H
; Scn8a
med-jo
 mice and littermate Scn1a
R1648H/R1648H
 controls are 
shown. Survival was monitored until 100 days of age. All genotypes had n = 11-16. 
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Discussion 
One characteristic feature of GEFS+ is the wide range of seizure types and 
severities frequently seen among family members with the same SCN1A mutation (23, 
24, 28). Based on these observations, we hypothesized that the variable clinical 
presentation in GEFS+ is possibly due to contributions from additional genetic modifiers.  
Even though it is well recognized that genetic modifiers can influence the clinical 
presentation of a disorder, we know of relatively few human modifier genes. Cystic 
fibrosis (CF) represents one good example of a monogenic human disease with a known 
genetic modifier. CF results from recessive mutations in CFTR, a cAMP-dependent 
chloride channel (29). Multiple studies have shown a significant association between two 
transforming growth factor-β (TGF-β) polymorphic variants and lung disease severity in 
CF (30, 31). TGF-β is an inflammatory cytokine and directly inhibits CFTR function 
(32). As a result, polymorphisms that increase circulating TGF-β levels are more 
common in patients with severe lung disease. 
Although genetic interactions have been difficult to demonstrate in epilepsy 
patients, model organisms can help in the search for genetic modifiers of seizure severity. 
We previously demonstrated that mutations in other ion channels could modify 
spontaneous seizure activity and lifespans of Scn1a
KO/+
 and Q54 mutants (17, 22). In the 
presence of the Scn8a
med-jo
 allele, the severe seizure phenotype of Scn1a
KO/+
 mice was 
dramatically ameliorated (22). In contrast, the Kcnq2
V182M/+
 and Szt1 mutations 
exacerbated the epilepsy phenotype of Q54 mice (17). 
Here we demonstrated Scn2a, Kcnq2 and Scn8a mutant alleles modified the 
phenotype of Scn1a
R1648H/+
 mice. This supports genetic modification as one mechanism 
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by which the clinical presentation of GEFS+ can be altered. The genetic interactions 
between these ion channels imply that variants within Scn2a, Kcnq2 and possibly Kcnq3, 
may exacerbate the clinical presentation of GEFS+, shifting it to a more severe part of the 
GEFS+ spectrum. As previously observed with Scn1a
KO/+
 mutants, the Scn8a
med-jo
 allele 
could rescue the increased susceptibility to flurothyl induced GTCS in Scn1a
R1648H/+
 mice 
by raising seizure thresholds to a level comparable to wildtype littermates (22). In 
addition, while Scn1a
R1648H/R1648H
 mutants do not survive more than 26 days, 47% of 
Scn1a
R1648H/R1648H
; Scn8a
med-jo
 mutants were still alive after 100 days. These results 
demonstrate that altered Scn8a function is capable of compensating for abnormalities in 
neuronal excitability caused by Scn1a mutations. These results suggest that selective 
blocking of Scn8a may be similarly protective in patients with epilepsy. Interestingly, 
although Scn8a
med-jo
 heterozygotes have increased resistance to convulsive seizures, we 
recently reported they do have spontaneous absence seizures, characterized by 
hypersynchrony of the thalamocortical system (20). This underscores the idea that the net 
effect of sodium channel dysfunction in different neuronal circuits is highly dependent on 
the channel composition and synaptic function within each circuit.  
In contrast, whereas Scn1a
R1648H/+
 mice have infrequent, adult-onset generalized 
seizures, the presence of either the Q54 or Kcnq2
V182M/+
 alleles resulted in severe, 
juvenile-onset generalized seizures and shortened lifespan. Recordings of neurons 
isolated from Scn1a mutant mice suggest there is decreased GABAergic 
neurotransmission in the hippocampus and cortex (7, 26, 27). In F1. Scn1a
R1648H/+
;Q54 
double mutants, the combination of increased excitability of pyramidal neurons due to the 
Scn2a mutation and decreased inhibition from the Scn1a mutation resulted in severe 
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generalized seizures and lethality. Reduced GABAergic inhibition may prevent localized 
seizure termination, resulting in secondary generalization of seizures and the more severe 
phenotype. Similarly, it was demonstrated that loss of M-current in Kcnq2 mutants 
resulted in hyperexcitability of hippocampal pyramidal CA1 neurons, which in 
combination with reduced GABAergic inhibition, may permit secondary generalization 
of seizures in double F1. Scn1a
R1648H/+
; Kcnq2
V182M/+
 mutants (33, 34). Alternatively, 
because these genes have widespread expression in the brain, it is possible that the severe 
phenotype observed in double mutant mice was the result of primary generalized 
seizures.  
Given that the Scn1a
R1648H/R1648H
;Scn8a
med-jo
 and F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 
compound mutants were on mixed genetic backgrounds, the respective 47% and 42% 
survival rates observed raises the possibility that genetic variants which differ between 
the B6 and 129 inbred strains may influence disease severity. Alternatively, the increased 
mortality between P20 and P40 in the double mutant heterozygotes may reflect a more 
vulnerable juvenile stage due to ongoing maturation processes in the developing brain. In 
humans, KCNQ2 dysfunction leads to BFNC, an epilepsy disorder affecting neonates that 
typically remits by one year of age. The spontaneous remission of BFNC appears to 
correlate with brain maturation (15). However, it is also plausible that the observed 
survival rates are due to stochastic events.  
Together with our previous study analyzing the B6.Q54;Kcnq2
V182M/+
 mice, our 
observations from F1. Scn1a
R1648H/+
;Kcnq2
V182M/+
 mutants illustrate that M-channel 
dysfunction in a background of abnormal excitability promotes seizure initiation and 
increases seizure severity. This suggests that increasing M-current may be of therapeutic 
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benefit in individuals with generalized epilepsy. The M-current enhancer ezogabine has 
therapeutic benefit as an adjunctive therapy in patients with drug-resistant focal epilepsy 
(35-37) 
Our findings show that voltage-gated ion channel variants can modify the 
phenotype of a mouse model of GEFS+ and therefore suggest that coding and possibly 
noncoding variants in Scn2a, Scn8a and Kcnq2 may influence clinical presentation and 
severity in patients with SCN1A mutations. The demonstrated genetic interactions 
between Scn1a, Scn2a, Scn8a and Kcnq2, together with previous reports showing a 
genetic interaction between Scn2a and Kcnq2, and Kcna1 and Cacna1a, support the 
notion that neuronal firing patterns are determined by the net sum of voltage-gated ion 
channel activity (17, 38). Hence, screening patients for mutations in a panel of selected 
ion channel genes may improve the utility of molecular diagnosis for risk assessment and 
guiding disease treatment. Traditional single gene screening approaches will be replaced 
by next-generation sequencing technologies, which will enable targeted re-sequencing of 
panels of selected genes, or whole exome analysis. Clinical diagnostic testing using next-
generation sequencing of gene panels is already being applied to epilepsy genetics 
(GeneDx) and are likely to replace single gene testing in the near future.  
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
 
Summary 
Epilepsy is a common neurological disease, affecting almost 3 million Americans 
and 1% of the worldwide population (1).  Considered a spectrum disorder, epilepsy has 
more than 25 associated syndromes. These range from the severe and debilitating Dravet 
and Lennox Gastaut syndromes to the mild and treatable conditions of GEFS+ (Genetic 
Epilepsy with Febrile Seizure Plus) and absence epilepsy (2-4). 
Two-thirds of patients diagnosed with epilepsy have no known cause for their 
disease, however recent evidence suggests most result from complex genetic interactions 
(5, 6). Mutations identified in nicotinic acetylcholine and GABA receptors, chloride 
channels and voltage-gated potassium and sodium channels are known to be responsible 
for monogenic epilepsies (7). Identification of these genes provided clues about the 
etiology of common epilepsy syndromes with more complex inheritance.  
Mutations in voltage-gated sodium channels are responsible for several types of 
human epilepsy, including GEFS+, Benign Familial Neonatal-Infantile Seizures 
(BFNIS), Dravet and Ohtahara syndromes (8-10). Family members who inherit the same 
epilepsy-associated sodium channel mutation frequently have clinical phenotypes that 
vary dramatically. This is seen in both GEFS+ and Dravet syndrome. This suggests that 
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other factors, possibly genetic, modify the primary mutation, resulting in a more or less 
severe phenotype.  
Mouse models have been generated to study the genetic basis of epilepsy. Often, 
the genetic strain background alters the disease phenotype, suggestive of genetic 
modifiers in epilepsy. The Scn2a
Q54
 (Q54) transgenic mouse model has a gain-of-
function mutation that results in persistent sodium current and epilepsy (11). On the 
C57BL/6J (B6) strain background, B6.Q54 mice have infrequent, adult-onset focal motor 
seizures and a 75% survival rate beyond six months of age (12). When crossed with the 
SJL/J (SJL) strain, the resulting F1.Q54 offspring experience high seizure frequency with 
juvenile onset and less than 25% survival until six months of age (12). We mapped two 
dominant loci that modify seizure susceptibility in Q54, designated Moe1 (Modifier of 
Epilepsy) on chromosome 11 and Moe2, on chromosome 19 (12).  
Chapter II focused on fine-mapping and narrowing of the Moe1 interval. We 
utilized interval-specific congenic lines spanning the Moe1 locus and RNA-Seq to 
identify candidate modifier genes of the Q54 seizure phenotype. Cacna1g and Hlf were 
selected among the top Moe1 candidates.  
Cacna1g, encoding the T-type calcium channel α1 subunit, was prioritized as a 
top female candidate modifier gene of the Moe1 locus based on previous research 
attributing Cacna1g mutations to human and mouse epilepsy (13-15). Cacna1g was 
hypothesized to modify the Q54 seizure phenotype based on the significant strain-
specific differences in expression profiles of transcripts which have functional kinetic 
diversity (13). Cacna1g channels preferentially expressed in SJL females reduce 
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synchronous thalamocortical oscillations, a common feature of epilepsy, while B6 
females express Cacna1g channels prone to hyperexcitability (13, 16-18).  
Hlf, encoding hepatic leukemia factor, a PAR bZIP transcription factor, was 
prioritized as a top candidate modifier gene of the Moe1 locus in males. This was based 
on previous research of a PAR bZIP transcription factor family knockout mouse model 
that experienced spontaneous GTCS and absence seizures (19). Further analysis of the 
model revealed a reduction in PDXK, a key enzyme involved in the conversion of 
pyridoxine to pyridoxal 5’ phosphate (PLP) (19). PLP is a key coenzyme involved in 
amino acid and neurotransmitter metabolism, including GABA and glutamate (20). PLP 
has a substantial connection with human and mouse epilepsy (20-22). Hlf was 
hypothesized to modify the Q54 seizure phenotype by contributing to strain-specific 
PDXK and PLP levels (13). Hlf is expressed at a significantly reduced level in B6 males 
compared to SJL (13). Furthermore, we observed a trend toward significant reduction 
(p=0.135) of PDXK expression in B6 males compared to SJL by RNA-Seq (N. Hawkins 
and J. Kearney, unpublished observations). These reductions in B6 may decrease PLP 
levels, consequently increasing seizure susceptibility.  
Chapter III focused on assessing the modifier potential of Cacna1g and Hlf. 
Through generation of Cacna1g BAC transgenic (SJL.1G5) and Hlf targeted knockout 
(B6.Hlf 
KO/+
) animal models, we systematically evaluated the ability of Cacna1g 
transgenic expression or loss of Hlf to alter seizure severity of the Q54 phenotype.  
We tested the candidate modifier gene Cacna1g by crossing the BAC transgenic 
SJL.1G5 line with B6.Q54 to generate double mutant mice. Double transgenic 
F1.1G5;Q54 males, not females, had significantly more seizures than F1.Q54 controls. 
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Although data from Chapter II suggested Cacna1g was a female-specific modifier, results 
from female F1.1G5;Q54 mice were difficult to interpret due to the possibility that the 
transgene may be subject to X-inactivation (13). These results suggest Cacna1g is a 
genetic modifier of the male F1.Q54 phenotype. Future evaluation of additional BAC 
transgenic lines with autosomal integration of the transgene will confirm if Cacna1g is a 
genetic modifier of the female F1.Q54 phenotype. 
To evaluate the contribution of Hlf on the seizure phenotype of Q54 mice, we 
generated double mutant mice on two genetic strain backgrounds by crossing          
B6.Hlf 
KO/+
;Q54 males with B6.Hlf 
KO/+
 or SJL females. On the F1 strain, no significant 
differences in seizure frequency or survival were observed between heterozygous 
knockout F1.Hlf 
KO/+
;Q54 mice and F1.Q54 controls in either sex. On the B6 strain, 
double mutant homozygous knockout B6.Hlf 
KO/KO
;Q54 males experienced GTCS not 
traditionally seen in the B6.Q54 model. Although no overt seizure phenotype was 
observed in either heterozygous B6.Hlf 
KO/+
;Q54 or homozygous B6.Hlf 
KO/KO
;Q54 
females, these mice were born at significantly reduced ratios than expected. The ratio 
shift suggests reduced viability of B6.Hlf 
KO/KO
;Q54 females. Overall, these results 
suggest that total loss of Hlf is detrimental to the B6.Q54 phenotype. 
In addition to seizure analysis, we evaluated our Hlf hypothesis by testing the 
effects of altering dietary pyridoxine on the Q54 phenotype. We hypothesized that a 
pyridoxine deficient diet would increase seizure frequency, based on past data which 
demonstrated that mice maintained on a deficient diet experienced increased seizure 
frequency (23-25). B6.Q54 females on the pyridoxine deficient diet had increased seizure 
frequency and reduced survival compared to controls. While the B6.Q54 male seizure 
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phenotype was not altered, neurochemistry studies showed B6.Q54 males maintained on 
the deficient diet had significant levels of proline detected in their brains, indicating an 
altered metabolic state. F1.Q54 males maintained on the deficient diet trended toward 
increased seizure frequency, while there was no change in F1.Q54 females. 
Neurochemistry studies showed F1.Q54 males had significant changes in glutamate and 
GABA concentrations compared to controls. These results suggest that maintaining 
adequate dietary pyridoxine levels is important when there is an underlying epilepsy risk. 
We hypothesized that a pyridoxine enriched diet would decrease seizure 
frequency, given that pyridoxine dependent epilepsies are successfully treated with PLP 
(21). No reduction in seizure frequency was observed in B6.Q54 males or females 
maintained on the pyridoxine enriched diet. F1.Q54 females maintained on the 
pyridoxine enriched diet had no changes in seizure frequency or survival. Paradoxically, 
F1.Q54 males had increased seizure frequency and reduced survival on the enriched diet 
compared to controls. These results suggest that dietary supplementation with pyridoxine 
megadoses offer no additional benefit. 
Finally, Hlf was shown to modify the Dravet phenotype of Scn1a
KO/+
 
heterozygous knockout mice. By four weeks of age, only 45% of double heterozygous 
knockout F1.Hlf 
KO/+
;Scn1a
KO/+
 mice survived compared to 71% of F1.Scn1a
KO/+
 
controls. This further supports Hlf as a genetic modifier of epilepsy as loss of Hlf alters 
two diverse epilepsy syndromes.   
Chapter IV focused on a functional candidate gene approach to evaluate known 
epilepsy mutations Q54 and Kcnq2
V182M/+
 on the phenotype of the Scn1a
R1648H/+
 epilepsy 
model. To assess the modifier potential of Q54 and Kcnq2
V182M/+
 mutations, we generated 
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double mutant mice and monitored seizure activity by ECoG and survival. Double mutant 
F1.Scn1a
R1648H/+
;Q54 and F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 mice exhibited GTCS with 
100% and 42% mortality by P25, respectively, unlike their single mutant control 
littermates. This suggests that genetic interaction between ion channels is one mechanism 
which contributes to the variable clinical presentation of inherited epilepsies. 
 
Implications for Epilepsy  
 Complex genetics are likely responsible for the majority of epilepsy cases with no 
known origin (5, 6). Several Dravet and GEFS+ voltage-gated sodium channel gene 
mutations result in variable expressivity of an epilepsy phenotype. While some 
individuals have a severe, debilitating seizure diagnosis, many have remitting seizures or 
no phenotype at all. This trend is likely a result of complex inheritance of protective and 
risk alleles in multiple genes. Mildly affected patients have possibly inherited protective 
alleles that reduced or prevented seizure activity. Alternatively, individuals with a more 
devastating phenotype likely inherited risk alleles that altered network function and 
resulted in a hyperexcitable, seizure-prone brain. Hypothesized epilepsy modifier genes 
responsible for the altered phenotype are relatively unknown. Our lab previously 
identified a modifier gene in mice that was subsequently shown to contribute to epilepsy 
risk in human patients (26). Kcnv2, encoding the voltage-gated potassium subunit Kv8.2, 
was identified as a modifier gene that influences the Q54 epilepsy phenotype (26). Kcnv2 
forms functional potassium channels by complexing with another potassium channel 
subunit, Kcnb1, which encodes Kv2.1, the major contributor to delayed rectifier 
potassium current (26). This Kv8.2/Kv2.1 heteromeric configuration results in altered 
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delayed rectifier channel kinetics (27, 28). In human epilepsy patients, two KCNV2 
missense variants were detected and when coexpressed with KCNB1, resulted in 
increased suppression of delayed rectifier potassium currents (26). Recently, a KCNB1 
variant was identified by exome sequencing of infantile spasm and Lennox-Gastaut 
families (29). Hlf was identified as a candidate modifier of the Q54 epilepsy phenotype 
due to its hypothesized influence on the pyridoxine pathway (13, 19). Traditional 
pyridoxine dependent epilepsies are defined by severe neonatal seizures that are 
successfully treated with pyridoxine or PLP, not classical AEDs (30).  Recent research 
revealed a “hidden” pyridoxine deficient epilepsy patient whose phenotype resembled 
Dravet syndrome, which is uncharacteristic of pyridoxine dependent epilepsies (30). The 
patient was screened for two genes in the pyridoxine pathway, ALDH7A1 and PNPO. 
(30).  A pathogenic mutation was identified in ALDH7A1, suggesting some unexplained 
epilepsies may result from pyridoxine deficiencies (30).  This further supports Hlf as a 
candidate modifier gene of an epilepsy phenotype as mutations in Hlf may reduce the 
efficiency of the pyridoxine pathway and thus increase seizure susceptibility. This 
demonstrates that identification of mouse epilepsy modifier genes can directly influence 
discovery of human epilepsy modifier genes.  
We have highlighted several examples throughout Chapters I-IV demonstrating 
that exacerbated or ameliorated epilepsy phenotype result from combining mutations 
from two different genes. This suggests that variants in multiple genes may modify the 
clinical phenotype in human epilepsy. This is particularly important for advancements in 
diagnostic and long-term prognostic capabilities as well as in designing novel therapeutic 
targets. Patients can wait months or even years to receive a specific epilepsy diagnosis. 
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While genetic testing in epilepsy is more accessible, especially in the more severe 
epileptic encephalopathies such as Dravet syndrome, its full impact has not yet been 
attained. Recent exome sequencing projects have started to identify novel genes 
responsible for epilepsy with a previously unknown origin, but exome sequencing is not 
yet routinely used in the clinic (9, 29, 31). Moreover, even if a hypothesized disease-
causing mutation in a gene is detected, prognosis is uncertain. For example, mutations in 
SCN1A can lead to the devastating Dravet syndrome or the very treatable GEFS+.  
Complicating things further is the phenotypic variability often seen in patients with the 
same mutation. 
By identifying genetic modifiers of epilepsy in mice, including Cacna1g and Hlf, 
improvements in both patient diagnosis and prognosis can occur. While genetic tests 
often include calcium channels, screening for variants in calcium and additional ion 
channels in the same patient may predict a possible severe seizure phenotype. 
Furthermore, adding modifier genes to genetic screens, including Hlf, may advance 
prognosis efficiency. Detection of a primary mutation with additional variants in modifier 
genes may suggest a disease course. For example, if a SCN1A positive GEFS+ patient 
also has an Hlf variant, we might predict a more severe phenotype. Alternatively, if the 
patient has inherited a protective modifier allele, we could predict a mild phenotype. 
Identification of epilepsy modifier genes can also advance therapeutics. Current 
antiepileptic medications mainly target GABA receptors, voltage-gated sodium channels 
and calcium channels (32). A third of epilepsy patients are unable to attain seizure control 
using these medications (33). For patients who are seizure free, many have tried at least 
two drugs before achieving seizure control (33, 34). Furthermore, controlled epilepsies 
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frequently are a result of combination therapy, with patients taking at least two drugs 
simultaneously (33, 34). The pharmacoresistance observed in epilepsy patients is 
hypothesized to result from both genetic and environmental factors (35, 36). If we focus 
drug discovery efforts to non-traditional targets, like modifier genes, the novel 
therapeutics generated may alleviate seizure symptoms with reduced side effects. Since 
currently available drugs act on broad pathways like GABA, many patients experience 
extreme drowsiness or fatigue. Through targeting modifier genes, novel drugs may 
prevent seizures intrinsically rather than universally targeting and sedating brain activity.   
To test Cacna1g as a potential drug target for epilepsy treatment, a high 
throughput screen to identify novel pharmacological inhibitors of Cacna1g would first be 
performed.  Positive candidates from the screen would be further evaluated using whole-
cell electrophysiology. Using HEK cells stably expressing Cacna1g , drug candidates 
would be assayed to identify those which inhibit calcium currents in a dose-dependent 
manner. The ideal drug would specifically target Cacna1g, therefore control experiments 
testing T, L, P, Q and N calcium channels is needed. Once a Cacna1g targeted drug is 
identified and validated in vitro, it can advance to in vivo testing. Essential experiments 
include seizure threshold testing to determine whether the drug raises the threshold to 
seizure induction compared to placebo treatment and EEG recordings of calcium channel 
mutants with epilepsy to determine if drug treatment reduces or prevents seizures.  
To test Hlf as a potential drug target for epilepsy treatment, the molecular basis of 
Hlf function would first be determined. Currently, we hypothesize Hlf acts on the 
pyridoxine pathway, but it is unknown what this transcription factor regulates or where in 
the pathway it has its influence. Through the use of chromatin immunoprecipitation and 
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next-generation sequencing of immunoprecipated DNA (ChIP-seq), we can identify 
regions of the genome that are potentially targeted and bound by Hlf. Once these regions 
are determined, we can test the identified gene candidates to assess their influence on 
seizure susceptibility. We can generate a transgenic or knockout mouse model of each 
candidate gene to determine if spontaneous seizure activity occurs or if a reduced 
threshold to induced seizures exists. To further validate each model and bridge the 
candidate gene(s) and Hlf to the pyridoxine pathway, we can test if administration of PLP 
can prevent seizure activity or extend the threshold to induced seizures.  
Verification of Cacna1g and Hlf as epilepsy modifier genes will suggest new 
targets for improved treatment of epilepsy and advance molecular diagnostic capabilities 
by identifying those patients who are most at-risk for developing severe epilepsy. 
 
 
Future Directions 
 
Investigation of additional candidate genes  
 We selected Cacna1g and Hlf as top priority candidate genes for evaluation of 
their potential modifier effects on the Q54 seizure phenotype. However other genes, 
including Cacnb1, Slc25a39 and Pnpo, were also considered strong candidate modifier 
genes at the Moe1 locus (Table 2.4). Cacnb1 encodes a calcium β subunit and has 
previously been linked to epilepsy (37-39). RNA-Seq identified a significant expression 
difference in the Cacnb1-006 transcript between B6 and SJL females. Interestingly, the 
Cacnb1-006 transcript is thought to act as a long non-coding RNA (lncRNA) (13). To 
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evaluate the modifier potential of Cacnb1, a targeted Cacnb1-006 siRNA could be 
utilized to knockdown the lncRNA in the Q54 mouse model. Furthermore, we could 
determine the Cacnb1 lncRNA targets to understand how it may affect excitability. 
 We also hypothesized a protective modifier gene is located within the Moe1 locus 
(13). Cltc and Dynll2 were suggested as top candidate genes within the protective region. 
By generating animal models overexpressing Cltc or Dynll2, we can evaluate if each gene 
has a protective effect on the Q54 phenotype. Furthermore, identification of protective 
alleles may provide novel therapeutic targets which have the ability to treat seizures with 
fewer side effects.  
 
Comprehensive analysis of Cacna1g and Hlf modifier effects 
To verify the full modifier potential of Cacna1g, it is necessary to generate and 
evaluate additional Cacna1g BAC transgenic lines. Recent pronuclear injections of the 
BAC clone containing Cacna1g (RP23-65I14) into B6 fertilized oocytes at the University 
of Michigan Transgenic Animal Model Core resulted in two transgenic founders, 1G3 
and 1G6. BAC integrity was preliminarily analyzed, suggesting both transgenics have 
complete integration of the construct. At this time, the 1G3 male transgenic founder has 
transmitted the transgene to N1 offspring while the 1G6 female founder has not.  
Hlf was verified as a modifier of the Q54 phenotype. Further investigation is 
needed to assess the mechanism of the Hlf modifier effect. Most importantly, ECoG 
analysis of homozygous B6.Hlf 
KO/KO
;Q54 and heterozygous B6.Hlf 
KO/+
;Q54 mice is 
crucial. This will confirm GTCS events seen during phenotyping as well as identify 
additional abnormal brain activity, like absence seizures. Female B6.Hlf 
KO/+
,          
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B6.Hlf 
KO/+
;Q54 and B6.Hlf 
KO/KO
;Q54 mice were born at significantly altered ratios than 
expected, suggesting reduced female viability. Future studies should include determining 
when B6.Hlf 
KO/+
;Q54 and B6.Hlf 
KO/KO
;Q54 females are being lost. Hlf was also 
identified as a modifier of survival of Dravet mice, an additional epilepsy model. To 
evaluate if F1.Hlf 
KO/+
;Scn1a
KO/+
 mice are dying significantly earlier compared to controls 
due to increased seizure frequency or severity, ECoG recordings are necessary. 
Furthermore, we determined the B6.Hlf 
KO/+ 
mouse model contains roughly ~45 Mb of 
129 S2/SvPas ES cell DNA on chromosome 11. This is problematic, as it adds a third 
genetic strain into our mouse crosses. Due to the original 129 construct DNA being 
present, B6.Hlf 
KO/+
;Q54 and B6.Hlf 
KO/KO
;Q54 offspring are actually F1.(129 X B6) and 
homozygous 129, respectively, in Moe1 instead of congenic B6. Moreover, from ISC line 
production (Chapter II) we are aware that multiple recombination “hot-spots” exist within 
Moe1. This may explain the inconsistency observed in seizure frequency and survival of 
B6.Hlf 
KO/+
;Q54 and B6.Hlf 
KO/KO
;Q54 mice. Offspring may have different regions of 129 
present in Moe1 due to recombination. To identify if recombination of B6 and 129 
regions along chromosome 11 is responsible for the discrepancies observed in the Hlf 
KO/+
 
X Q54 phenotyping crosses, genotyping must be performed on all phenotyped offspring. 
This will determine if recombination occurred and if so, we can categorize offspring into 
groups based on the amount of 129 DNA present.  
Finally, to determine if these modifier genes are relevant to human epilepsy risk,  
it is essential to screen epilepsy patients for genetic variation in HLF and CACNA1G.This 
approach was utilized in our lab previously and validated the approach that identifying 
genetic modifier genes in mouse is translatable to human epilepsy gene detection (26). 
131 
 
Ohtahara syndrome as a result of Scn2a and Kcnq2 mutations  
 Since the publication of Hawkins et al, 2011 both SCN2A and KCNQ2 have been 
implicated by whole genome sequencing in Ohtahara syndrome  (9, 10, 40, 41). 
Hundreds of hours of ECoG data from F1.Scn1a
R1648H/+
;Q54 and 
F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 offspring and controls are available for analysis. These 
offspring may serve as compelling mouse models of Ohtahara syndrome. For Hawkins et 
al, the focus was to identify GTCS, absence and focal seizures. We did not examine 
ECoG data for other irregular features such as classic Ohtahara suppression burst 
patterns. Furthermore, brain histology was not performed on offspring. Ohtahara patients 
usually have severe brain abnormalities, including atrophy of the cortex, corpus callosum 
and cerebellum (10, 10, 42). Future studies should inspect ECoG data from 
F1.Scn1a
R1648H/+
;Q54 and F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 offspring and controls for 
Ohtahara characteristics. Additionally, brain histology of offspring may also support 
F1.Scn1a
R1648H/+
;Q54 and F1.Scn1a
R1648H/+
;Kcnq2
V182M/+
 offspring as Ohtahara models.  
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